

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Management of Acute Venous Thromboembolism Amongst Patients Discharged from Hospital

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022065
Article Type:	Research
Date Submitted by the Author:	30-Jan-2018
Complete List of Authors:	Bungard, Tammy; University of Alberta Hospital, Medicine Ritchie, Bruce; University of Alberta Faculty of Medicine and Dentistry, Hematology Bolt, Jennifer; Interior Health Authority, Senior's Health and Awareness Semchuk, William; Regina Qu'Appelle Health Region, Pharmacy Services
Keywords:	AUDIT, Anticoagulation < HAEMATOLOGY, Clinical audit < HEALTH SERVICES ADMINISTRATION & MANAGEMENT

SCHOLARONE™
Manuscripts

Peer Review Only

Management of Acute Venous Thromboembolism Amongst Patients Discharged from Hospital

Tammy J Bungard, BSP, PharmD*
Associate Professor of Medicine, Division of Cardiology
University of Alberta, Edmonton, Alberta

Bruce Ritchie, MD, FRCP(C)
Professor of Medicine, Division of Hematology
University of Alberta, Edmonton, Alberta
britchie@ualberta.ca

Jennifer Bolt, BScPharm, PharmD
When work was conducted: Residency and Education Coordinator, Pharmacy Services
Regina Qu'Appelle Health Region, Regina, Saskatchewan
Current: Clinical Pharmacy Specialist, Interior Health Authority
Kelowna, British Columbia
Jennifer.Bolt@interiorhealth.ca

William Semchuk, BSP, MSc, PharmD, FCSHP
Manager, Clinical Pharmacy Services,
Regina Qu'Appelle Health Region, Regina, Saskatchewan
Bill.Semchuk@rqhealth.ca

Text Word Count: 2,459

*Corresponding Author:

Dr. Tammy J Bungard
EPICORE Centre
362 Heritage Medical Research Centre
University of Alberta
Edmonton, AB T6G 2S2
Email: tammy.bungard@ualberta.ca
Phone: 780-492-3431 Fax: 780-492-6059

ABSTRACT:

Objective: To determine anticoagulant therapy at hospital discharge for patients with acute venous thromboembolism (VTE) and secondarily, to describe factors affecting choice of therapy.

Design: A retrospective chart review.

Setting: Hospitals in Edmonton, Alberta (N=4), Regina, Saskatchewan (N=2) and rural Alberta (N=3) from April 2014 to March 2015.

Participants: All patients discharged with an acute VTE were screened. Those with atypical clots, another indication for anticoagulation, pregnancy/breastfeeding or lifespan < 3 months were excluded.

Interventions: None.

Primary and secondary outcomes: Primarily, we identified the proportion of patients discharged from hospital with acute VTE that were prescribed either traditional therapy (parenteral anticoagulant \pm warfarin) or a direct acting oral anticoagulant (DOAC). Secondarily, management based on setting, therapy choice based on DVT versus PE, clot burden and renal function was compared. DOAC dosing was assessed (when prescribed), length of hospital stay based on therapy was compared, and planned follow-up in the community was described.

Results: Amongst the 695 patients included, most were discharged following a diagnosis of PE (82.9%) on traditional therapy (parenteral anticoagulant +/- warfarin) (70.2%) with follow-up by either a family doctor (51.5%) or specialist/clinic (46.9%) post-discharge. Regional variation was most evident between urban and rural sites. Of those prescribed a DOAC (28.3%), the majority were dosed appropriately (85.8%). DOAC use did not differ between those with DVT and PE, was proportionately higher for less severe clots, and declined with worsening renal function. Patients prescribed DOACs vs traditional therapy had shorter length of stays (4 versus 7 days, respectively).

1
2
3 **Conclusions:** Uptake of DOAC therapy for acute VTE was modest and may have been influenced by the
4 timing of the audit in relation to the approval of these agents for this indication. Future audits should
5 occur to assess temporal changes and ongoing appropriateness of care delivery.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This study consists of a large cohort of patients discharged with acute DVT or PE from 2 urban areas and 3 rural sites throughout an entire year, thereby providing a good reflection of practice patterns.
- All patient charts were reviewed for inclusion, thereby enabling accurate data capture of the acute VTE population.
- Although this audit occurred early in the licensing of DOACs for VTE, these data offer a benchmark for future usage as guidelines more aggressively incorporate the utilization of DOACs in this population.
- Given our study design, we were not able to collect data for patients following discharge from hospital, thereby prohibiting the assessment of patient outcomes.

FUNDING STATEMENT

Funding was received from Pfizer Canada (via Dr. Bungard) in the form of an unrestricted grant. The sponsor had no role in the protocol design, study conduct, analysis/interpretation of the findings or decision to publish.

COMPETING INTEREST STATEMENT

TJB has received honoraria for an advisory board for BMS-Pfizer and Boehringer Ingelheim, as well as honoraria for speaking from Bayer. TJB has received unrestricted grants from Pfizer and Bayer. BR has served on advisory boards, given sponsored lectures using his own slides and received travel expense remuneration for Bayer, Baxter, Boehringer-Ingelheim, CSL-Behring, Pfizer, Sanofi, Servier and Shire. In lieu of honoraria for these activities, the companies have given financial contributions to the University of Alberta. BR reports grants from Novo Nordisk, CSL-Behring and Baxter, all outside of this submitted work. JB has received speaker honoraria from Boehringer Ingelheim in the past two years. WS has

1
2
3 received honoraria from Bayer, Pfizer, Bristol Myers Squibb and Boehringer Ingelheim. He has served as
4
5 a consultant or on an Advisory Board for Bayer and Pfizer/Bristol Myers Squibb and he has received an
6
7 unrestricted research grant from Pfizer.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

INTRODUCTION

After over half a century of vitamin K antagonists as the only available oral anticoagulant therapy, several direct oral anticoagulants (DOACs) have been approved within the past 5 years for the acute treatment of venous thromboembolism (VTE).¹⁻⁴ The DOACs (rivaroxaban, dabigatran, apixaban and edoxaban) offer advantages over the traditional therapy of an injectable anticoagulant (typically low molecular weight heparin [LMWH]) overlapped with warfarin.⁵ Unlike warfarin therapy, all DOACs have standardized dosing regimens that lack the need for routine coagulation monitoring and offer a therapeutic effect within hours of administration. Rivaroxaban and apixaban do not require initial therapy with an injectable anticoagulant, further streamlining care delivery. Given this, the purpose of this study was to describe the management of acute VTE amongst patients discharged from hospitals within the Edmonton, Alberta and Regina, Saskatchewan areas as well as rural Alberta. Specifically, we sought to determine the anticoagulant therapy provided at hospital discharge for acute VTE and secondarily, to examine factors which may have influenced the therapy prescribed.

METHODS

Setting and Patients

A retrospective chart review was conducted at the 4 largest hospitals in Edmonton, Alberta (University of Alberta Hospital, Royal Alexandra Hospital, Misericordia Hospital, Grey Nuns Hospital), 3 rural hospitals in Alberta (Wetaskiwin Hospital, Westlock Healthcare Centre and Athabasca Healthcare Centre) and the 2 hospitals in Regina, Saskatchewan (Regina General Hospital and Pasqua Hospital). These areas were selected based on a collaboration of local investigators. All patients with a discharge diagnosis of deep vein thrombosis (DVT) (ICD-10 code I82 + sub-indices) or pulmonary embolism (PE) (ICD-10 code I26 + sub-indices) between April 1, 2014 and March 31, 2015 were screened. Atypical clot locations (e.g., axillary/subclavian veins, portal vein) were not included given their lack of enrollment in the large scale non-inferiority trials of the DOACs.⁶⁻¹¹ Patients were also excluded if they had another

1
2
3 indication for therapeutic anticoagulation, were not discharged alive, had an anticipated lifespan < 3
4 months (documentation of palliation or prognosis), were < 18 years of age, were discharged directly
5 from the emergency department or were pregnant or breastfeeding.
6
7

8 9 **Outcomes**

10
11
12 Primarily, we sought to determine the proportion of patients discharged from hospital with
13 acute VTE that were prescribed a traditional therapy (parenteral anticoagulant ± warfarin) or a DOAC.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

When prescribed, the use of DOACs was assessed for concordance with dosing regimens with Health Canada approved product monographs as per prescriptions in hospital and at the point of discharge.¹⁻⁴ DOAC dosing was considered concordant if therapy was provided with either a parenteral anticoagulant or the appropriate up front (larger dose) of rivaroxaban (15mg BID) or apixaban (10mg BID) for the appropriate duration (3 and 1 week, respectively). We also assessed the difference in length of hospital stay in patients prescribed a DOAC versus a traditional therapy, and with whom follow-up was to occur after discharge.

Notably, these data represent a detailed evaluation specific to patients hospitalized with acute VTE. Our audit also encompassed the cohort of patients discharged directly from emergency departments from all institutions. As per our pre-planned analysis, there are 2 other manuscripts under review; one detailing the emergency department cohort (see Supplementary file 1) and the other comparing (in aggregate amongst the urban settings) patents discharged directly from the emergency department versus those hospitalized (see Supplementary file 2).^{14,15}

Data sources and analysis

All data elements were extracted from the hospital –based charts by trained data abstractors (2 for Alberta-based sites and 1 for Regina-sites) and directly entered into the research electronic data capture (REDCap). As this was a retrospective chart review, missing data elements (such as weight) were identified and reported, accordingly.

Data analysis was performed at the Epidemiology Coordinating and Research (EPICORE) Centre. Data were collated and reported based on location, namely Edmonton area, Regina area and rural Alberta. Patients' characteristics were compared between sites using mean (SD) or median (IQR) as appropriate for the continuous data and proportions (%) for categorical data. Chi-square test was used to compare discharge therapies between sites and different groups. Statistical analysis was carried out on SAS version 9.4. Health Research Ethics Board approval was received through the University of Alberta (Pro00056384) for all Alberta sites, and via the Regina Qu'Appelle Health Region (REB 15-65) for the Regina sites.

RESULTS

A total of 958 charts were screened with 695 (72.5%) included (Figure 1). The most common reasons for exclusion were lack of an acute VTE diagnosis (39.9%) and another indication for therapeutic anticoagulation (23.6%). Overall, those included had an average age (\pm SD) of 63.3 ± 17.3 years, a median body weight of 85.5Kg and only a minority (3.5%) had a creatinine clearance (CrCl) <30 mL/min (Table 1). The majority of patients had PE (82.9%), particularly in the urban centres of Edmonton (84.4%) and Regina (80.8%), while the diagnosis of PE was lower in rural Alberta (63.3%). Based on the sPESI score, the majority with PE in Edmonton (66.5%) and Regina (58.8%) had a PESI score ≥ 1 , while rural Alberta was nearly half the patients (47.4%). The majority of patients admitted for DVT had a proximal clot; Edmonton (87.1%), rural Alberta (81.8%), Regina (69.6%). Of note, full leg ultrasounds were utilized in Regina while only above the knee ultrasounds were utilized in both Edmonton and rural Alberta.

1
2
3 The majority of patients (70.2%) were discharged from hospital on a traditional therapy
4 (parenteral anticoagulant +/- warfarin), with 28.3% receiving a DOAC (Table 2). Notably, Regina had the
5 highest rate of a warfarin-based regimen (60.8%), with less warfarin used in Edmonton (40.5%) and rural
6 Alberta (30%). Use of DOACs was most common in rural Alberta (57.9%), followed by Edmonton (28.3%)
7 and Regina (23.3%).
8
9

10
11
12 There was no difference in proportionate use of a DOAC for PE compared to DVT (28.0% and
13 30.3%, respectively; $P=0.61$). Patients having a sPESI score of 0 were more likely to be prescribed a
14 DOAC relative to those with a score ≥ 1 (33.3% and 24.3%, respectively; $P<0.0001$). Only a small portion
15 of patients in our study had distal DVTs (N=13) compared with proximal DVTs (N=99), and DOAC use was
16 not significantly different for distal DVTs (50%) compared to proximal DVTs (27.6%) ($P=0.14$).
17
18

19
20
21 Amongst the 197 patients prescribed a DOAC, the majority (97.5%) received rivaroxaban, with a
22 minority of patients receiving apixaban (N=3 [1.5%]) and dabigatran (N=2 [1.0%]). DOAC dosing for the
23 acute treatment of VTE was consistent with product monographs in 85.8% of patients. The majority of
24 inconsistent dosing with rivaroxaban was attributable to not having a full 3 weeks of therapy of higher
25 dose (rivaroxaban 15mg BID) prior to implementing the lower maintenance dose of 20mg daily
26 (N=25/28). Only a minority of patients had renal dysfunction with a CrCl $< 30\text{mL}/\text{min}$ (N=23 [3.5%]).
27 DOAC use declined with worsening renal function with 31.1% (161/517), 19.0% (23/121), and 4.4%
28 (1/23) prescribed a DOAC with a CrCl >50 , 30-50 and $<30\text{mL}/\text{min}$, respectively ($P<0.0001$).
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43
44 Combining all sites, median (IQR) length of stay was shortest amongst those prescribed a DOAC
45 (4 days [2.0, 9.0]) and longest for those transitioning from LMWH to warfarin therapy (7 days [4.0, 12.0])
46 ($P<0.0001$) (Table 3). At discharge, amongst the urban sites follow-up was to occur most commonly with
47 a VTE clinic/specialist (47.5% for Edmonton and 52.5% with Regina) whereas rural Alberta referred most
48 to family doctors (66.7%) (Table 2).
49
50
51
52
53

54 DISCUSSION

55
56
57
58
59
60

1
2
3 Amongst all sites, the majority (70.2%) of patients presenting with acute VTE were prescribed
4 traditional therapies (parenteral anticoagulant +/- warfarin) at hospital discharge, and 28.3% received a
5 DOAC. Rural Alberta had the greatest uptake of the DOACs (50%), followed by the Edmonton area
6 (28.3%) and Regina area (23.3%). Uptake of DOACs in rural Alberta is likely attributable to many factors,
7 including more limited laboratory availability for routine coagulation testing, primary care physicians
8 providing care within the hospital and hospital pharmacists who were comfortable with data pertaining
9 to the use of DOACs in this population. While we found no difference in the use of DOACs for PE relative
10 to DVT, DOACs were used more in patients with lower risk PE and normal renal function. When
11 prescribed, the majority of DOAC use (85.8%) was concordant with Canadian product labeling.
12
13

14
15 Our overall rate of DOAC use for acute VTE (28.3%) is similar to that reported amongst 328
16 patients discharged from Florence, Italy hospitals following acute PE (32.5%) during 2014 and 2015.¹⁶
17 These investigators assessed a time interval that partially overlapped with ours, and report an increase
18 in DOAC use from 2014 (23.2%) to 2015 (40.1%). A single site evaluation of therapy for an incident VTE
19 presentation amongst 256 patients in Montreal, Quebec Canada in 2013 found similar overall trends to
20 our study with most patients being treated with warfarin (54.7%) followed by LMWH alone (27.7%) and
21 rivaroxaban (17.6%).¹⁷ Unlike our study, those in the Quebec evaluation with DVT (N=94) were more
22 likely than those with PE (N=162) to receive rivaroxaban (28.7% and 11.1%, respectively). In terms of
23 clinical presentation of PE, a single site evaluation of 39 patients with PE being discharged from hospital
24 on a DOAC showed more use amongst those defined as low risk (83%), with overall DOAC use still being
25 high for those at intermediate-low risk (40%), intermediate-high risk (68%) and high risk (40%).¹⁶ Our
26 study found similar results in that more patients with a sPESI score of 0 (33.3%) received DOACs,
27 however DOACs were still used amongst those with a score of ≥ 1 (24.3%).
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51

52 Concordance with dosing for acute VTE in our study (85.8%) was similar to that reported in an
53 audit assessing the appropriateness of DOAC prescribing amongst 39 VTE patients in Australia (84.6%)¹⁸
54
55
56
57
58
59
60

1
2
3 and lower than that reported in a non-interventional study assessing the use of the appropriate initial
4 dosing of rivaroxaban (93.7%).¹⁹ Unlike our study wherein the majority of patients not receiving DOAC
5 dosing per the product monographs due to not receiving the appropriate up front rivaroxaban 15mg
6
7 BID, the non-interventional study reported that only 73% of patients went onto step down to
8 rivaroxaban 20mg daily.¹⁹ Unfortunately, we were not able to identify therapy changes beyond that
9
10 planned at hospital discharge within our study.

11
12
13
14
15
16
17 Given that initial therapy with an injectable anticoagulant is not required for both rivaroxaban
18 and apixaban and that routine coagulation monitoring is not performed with all of the DOACs, care
19 delivery with a DOACs compared to traditional therapy with a parenteral anticoagulant ± warfarin
20 should be simplified. Data from the North American cohort of patients enrolled in landmark trials
21 reports a significantly shorter length of stay for those receiving rivaroxaban (3.0 days [3.0-5.0])
22 compared to traditional therapy (4.0 days [3.0-6.0]; P=0.0004).²⁰ A single site evaluation in Quebec,
23 Canada affirmed the clinical trial data, and reported median length of stay to be shorter with
24 rivaroxaban use (3.5 days) relative to LMWH alone or warfarin therapy (6 days).¹⁷ Similarly, a single
25 American institution identified those discharged on rivaroxaban compared to warfarin had shorter
26 hospital stays (3.5 and 7 days, respectively; P<0.001).²¹ These data are consistent with ours, as patients
27 receiving a DOAC had a shorter median length of stay (Table 3).

28 29 30 31 32 33 34 35 36 37 38 39 40 41 **STRENGTHS AND LIMITATIONS**

42
43 We present data herein reflective of the largest cohort of patients with acute VTE being
44 discharged following hospitalization. For all sites, we reviewed all medical records with a discharge
45 diagnosis of deep vein thrombosis (DVT) (ICD-10 code I82 + sub-indices) or pulmonary embolism (PE)
46 (ICD-10 code I26 + sub-indices) over the span of a full year (April 2014 to March 2015). In doing so,
47 different sample sizes were identified from each area, with rural Alberta and Regina having fewer
48 patients (N=30 and N=120, respectively) than the Edmonton area (N=545). Despite the differences in
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 sample sizes, these data reflect local practices given the geographic populations and catchment areas
4
5 (Edmonton: 1,328,290 plus catchment of ~500,000; Regina: 230,020 plus catchment of 500,000; rural
6
7 Alberta 3 sites: 30,065) and that an entire year was assessed.²²⁻²⁶ The timing of our audit is reflective of
8
9 the early uptake of DOACs for the acute treatment of VTE given only rivaroxaban had Health Canada
10
11 approval throughout the entire time interval audited. Despite this, we identified reasonable uptake of
12
13 the DOACs (28.3%), with use that complied with product monograph labeling in the vast majority
14
15 (85.8%). This data can serve as a marker for future analyses wherein usage can be compared to assess
16
17 the uptake of this therapeutic approach over time as guidelines more aggressively incorporate the
18
19 utilization of DOACs in this population and clinicians become more comfortable with their use.
20
21
22

23 Our design (retrospective medical record review) was selected to allow us to accurately select
24
25 patients with acute VTE to ascertain practice patterns. Given the diverse geography and volume of
26
27 records to review, 3 data abstractors were necessary. A master key defining eligibility, data points to
28
29 collect and how to code variables in REDCap was used. Within REDCap, restrictions for variables were
30
31 programmed to minimize data entry error. Prior to finishing data collection at each site, quality
32
33 assurance reports were performed to ensure accuracy of data. As this was a record review, we were
34
35 limited only to information available in the hospital-based chart. Given this, some data elements were
36
37 not documented (e.g., weight, serum creatinine), leaving us to report data for those available.
38
39 Moreover, our design did not enable us to collect data following hospital discharge, limiting us from
40
41 determining if patients got their prescriptions filled or had complications following discharge.
42
43
44

45 CONCLUSION

46
47
48 In summary, we report the management of a large cohort of acute VTE patients being
49
50 discharged from hospitals within Canada. Over a time interval early in the approval process for DOACs
51
52 for the acute treatment of VTE, we report a modest uptake of DOACs (28.3%) that were, overall, dosed
53
54 correctly for the majority of patients (85.8%). Variation in therapies used was evident with the most
55
56
57
58
59
60

1
2
3 common regimen being warfarin-based in Regina (60.7%) and Edmonton (40.5%) and a DOAC in rural
4
5 Alberta (50.5%). Use of rivaroxaban was proportionately higher for less severe clots, and those
6
7 prescribed a DOAC had a shorter length of stay relative to those given traditional therapies. As time
8
9 evolves, it is anticipated use of DOACs will increase for the management of VTE. Practitioners and health
10
11 delivery systems should continue to consider the opportunity provided by the DOACs to simplify and
12
13 shorten hospital based care as further data emerges to support their place in therapy. Future
14
15 evaluations should occur to assess temporal changes, ongoing appropriateness of care delivery and the
16
17 impact that DOACs may have on healthcare system resource allocation.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Pfizer Canada Inc, Kirkland, Quebec and Bristol-Myers Squibb Canada, Montreal, Quebec. Eliquis™ Product Monograph. Montreal, Quebec.
http://www.pfizer.ca/sites/g/files/g10028126/f/201607/ELIQUIS_PM_184464_16June2016_E_mar_keted.pdf Accessed 9 February 2017
2. Daiichi Sankyo, Inc, Parsippany, NJ, USA (Manufacturer); Progress Therapeutics, Newmarket, Ontario (Importer and Distributer). Lixiana™ Product Monograph.
https://pdf.hres.ca/dpd_pm/00037831.PDF Accessed 9 February 2017
3. Boehringer Ingelheim Canada Ltd. Pradaxa™ Product Monograph, Burlington, Ontario.
<https://www.boehringer-ingelheim.ca/sites/ca/files/documents/pradaxapmen.pdf> Accessed 9 February 2017
4. Bayer Inc. Xarelto™ Product Monograph. Toronto, Ontario. Available:
<http://omr.bayer.ca/omr/online/xarelto-pm-en.pdf> Accessed 9 February 2017
5. Finks SW, Trujillo TC, Dobesh PP (2016) Management of venous thromboembolism: recent advances in oral anticoagulation therapy. *Ann Pharmacother* 50:486-501. doi: 10.1177/1060028016632785
6. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M et al for the AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. *N Engl J Med* 2013;369:799-808. doi: 10.1056/NEJMoa1302507
7. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H et al for the RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. *N Engl J Med* 2009;361:2342-52. doi: 10.1056/NEJMoa0906598

- 1
2
3 8. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Erikson H, Mismetti P et al. Treatment of acute
4 venous thromboembolism with dabigatran or warfarin and pooled analysis. *Circ* 2014;129:764-772.
5
6 doi: 10.1161/CIRCULATIONAHA.113.004450
7
- 8
9
10 9. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. *N Engl J*
11
12 *Med* 2010;363:2499-510. doi:10.1056/NEJMoa1007903
13
- 14 10. The EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary
15
16 embolism. *N Engl J Med* 2012;366:1287-97. doi:10.1056/NEJMoa1113572
17
- 18 11. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous
19
20 thromboembolism. *N Engl J Med* 2013;369:1406-1415. doi: 10.1056/NEJMoa1306638
21
- 22 12. Chan CM, Woods C, Shorr AF. The validation and reproducibility of the pulmonary embolism severity
23
24 index. *J Thromb Haemost* 2010;8:1509-1514. Doi: 10.1111/j.1538-7836.2010.03888.x.
25
- 26 13. Righini M, Roy PM, Meyer G, Verschuren F, Aujesky D, Le Gal G. The simplified pulmonary embolism
27
28 severity index (PESI): validation of a clinical prognostic model for pulmonary embolism. *J Thromb*
29
30 *Haemost* 2011;9:2001-2007. doi: 10.1111/j.1538-7836.2011.04469.x.
31
- 32 14. Bungard TJ, Ritchie B, Bolt J, Semchuk W. Management of acute venous thromboembolism for
33
34 patients discharged directly from the emergency department. *BMJ Open*, Under Review, February
35
36 2018.
37
- 38 15. Bungard TJ, Ritchie B, Bolt J, Semchuk W. A comparison of acute venous thromboembolism amongst
39
40 patients discharged directly from the emergency department versus hospitalized. *BMJ Open*, Under
41
42 Review, February 2018.
43
- 44 16. Masotti L, Vannucchi V, Poggi M, Landini G. Trends in length of hospital stay in acute pulmonary
45
46 embolism over the years. What is changing in the era of direct oral anticoagulants? *J Cardiovasc*
47
48 *Med* 2015;17:817-823. doi: 10.2459/JCM.0000000000000356
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 17. Dault R, Vanasse A, Blais L, Perreault S, Farand P, Le Templier G et al. Patterns of predictors of use
4 of anticoagulants for the treatment of venous thromboembolism following approval of rivaroxaban.
5
6 Clin Appl Thromb Hemost 2016;22:765-771. doi: 10.1177/1076029615611249
7
8
9
10 18. Pattullo CS, Barras M, Tai B, McKean M, Donovan P. New oral anticoagulants: appropriateness of
11 prescribing in a real-world setting. Int Med J 2016;46:812-818. doi: 10.1111/imj.13118
12
13
14 19. Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J et al. Safety and effectiveness of
15 oral rivaroxaban versus standard anticoagulation for the symptomatic deep-vein thrombosis
16 (XALIA): an international, prospective, non-interventional study. Lancet Haematol 2016;3:e12-21.
17
18 doi: hggp://dx.doi.org/10.1016/S2353-3026(15)00257-4
19
20
21
22
23 20. Bookhart BK, Haskell L, Bamber L, Wang M, Schein J, Mody SH. Length of stay and economic
24 consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE:
25 findings from the North American EINSTEIN clinical trial program. J Med Econ 2014;17:1691-695.
26
27 doi: 10.3111/13696998.2014.946993
28
29
30
31
32 21. Desai A, Desai A, Calixte R, Aparnath M, Hindenburg A, Salzman S et al. Comparing length of stay
33 between patients taking rivaroxaban and conventional anticoagulants for treatment of venous
34 thromboembolism. Lung 2016;194:605-611. doi:10.1007/s00408-016-9898-8
35
36
37
38
39 22. Population of Edmonton area, accessed October 31, 2017:
40
41 [http://globalnews.ca/news/1824910/edmonton-region-has-canadas-2nd-highest-population-](http://globalnews.ca/news/1824910/edmonton-region-has-canadas-2nd-highest-population-growth-stats-canada/)
42 [growth-stats-canada/](http://globalnews.ca/news/1824910/edmonton-region-has-canadas-2nd-highest-population-growth-stats-canada/)
43
44
45
46 23. Population of Regina, accessed October 31, 2017:
47
48 <http://www.leaderpost.com/life/Regina+population+cracks/9553267/story.html>
49
50
51 24. Athabasca Population, accessed October 31, 2017: [http://www.city-data.com/canada/Athabasca-](http://www.city-data.com/canada/Athabasca-Town.html)
52 [Town.html](http://www.city-data.com/canada/Athabasca-Town.html)
53
54
55
56
57
58
59
60

1
2
3 25. Westlock Population, accessed October 31, 2017: [http://www.city-data.com/canada/Westlock-](http://www.city-data.com/canada/Westlock-Town.html)
4
5 Town.html
6

7
8 26. Wetaskiwin Population, accessed October 31, 2017:
9
10 <https://www.wetaskiwin.ca/DocumentCenter/View/1039>
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

AUTHOR CONTRIBUTIONS

TJB contributed to the design of the work, the acquisition, analysis and interpretation of the data. TJB drafted the original manuscript, approved the final version to be published and is accountable for all aspects of the work related to accuracy or integrity. BR contributed to the design of the work, the interpretation of the data and critically revised the manuscript. BR approved the final version to be published and is accountable for all aspects of the work related to accuracy or integrity. JB contributed to the acquisition and interpretation of the data, critically revised the manuscript and approved the final version to be published. JB is accountable for all aspects of the work related to accuracy or integrity. WS contributed to the design, acquisition and interpretation of the data, critically revised the manuscript and approved the final version to be published. WS is also accountable for the accuracy and integrity of this work.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Patient Flow

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2018-022065 on 31 October 2018. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

Table 1: Baseline Characteristics

	Total	Edmonton	Rural Alberta	Regina
Screened (N)	958	736	41	181
Included (N, %)	695 (72.5%)	545 (74.0%)	30 (73.2%)	120 (66.3%)
Male (N, %)	350 (50.4%)	282 (51.7%)	16 (53.3%)	52 (43.3%)
Mean age (mean \pm SD)	63.3 \pm 17.3	63.8 \pm 17.2	64.2 \pm 16.9	60.4 \pm 17.6
Weight Documented (N, %) ^a	680 (97.8%)	534 (98.0%)	28 (93.3%)	118 (98.3%)
Weight, Kg (Median, IQR)	85.5 (70.0, 106.0)	84.5 (70.0, 106.0)	84.3 (71.0, 98.3)	90.5 (70.0, 110.0)
CrCl Documented (N, %) ^a	661 (95.0%)	515 (94.5%)	29 (96.7%)	117 (97.5%)
< 30 mL/min	23 (3.5%)	20 (3.9%)	1 (3.5%)	2 (1.7%)
30-49 mL/min	121 (18.3%)	96 (18.6%)	3 (10.3%)	22 (18.8%)
> 50 mL/min	517 (78.2%)	399 (77.5%)	25 (86.2%)	93 (79.5%)
VTE				
DVT	119 (17.1%)	85 (15.6%)	11 (36.6%)	23 (19.2%)
Distal	13 (10.9%)	7 (8.2%)	0	6 (26.1%)
Proximal ^b	99 (83.2%)	74 (87.1%)	9 (81.8%)	16 (69.6%)
Not documented	7 (5.9%)	4 (4.7%)	2 (18.2%)	1 (4.3%)
PE and PE + DVT ^c	576 (82.9%)	460 (84.4%)	19 (63.3%)	97 (80.8%)
PE – Simplified PESI Score: ^d	567 (98.4%)	451 (98.0%)	19 (100%)	97 (100%)
0 point	201 (35.4%)	151 (33.5%)	10 (52.6%)	40 (41.2%)
\geq 1 points	366 (64.6%)	300 (66.5%)	9 (47.4%)	57 (58.8%)
History of:				
Cancer	158 (22.7%)	119 (21.8%)	10 (33.3%)	29 (24.2%)
Pulmonary disease	143 (20.6%)	114 (20.9%)	6 (20.0%)	23 (19.2%)
Prior VTE	100 (14.4%)	81 (14.9%)	6 (20.0%)	13 (10.8%)
Recent surgery	32 (4.6%)	23 (4.2%)	0	9 (7.5%)
Length of Stay (median, IQR)	6.0 (3.0, 11.0)	6.0 (3.0, 11.0)	5.5 (3.0, 13.0)	6.0 (3.0, 9.0)

CrCl=Creatinine Clearance; SD=Standard Deviation; IQR=Interquartile Range; PE=Pulmonary Embolism; DVT=Deep Vein Thrombosis; PESI=Pulmonary Embolism Severity Index; LOS=Length of Stay

^anot all patients had weight and serum creatinine documented in the chart

^bCombined popliteal, femoral, common femoral, and iliac

^ccombined PE with PE+DVT and report it all as PE

^dPESI score could not be calculated in 9 patients due to missing variable(s)

Table 2: Therapy at Discharge and Follow-Up Plan for Hospitalized Cohort

	Total	Edmonton	Rural Alberta	Regina	P Value
VTE (All Combined)					<0.0001
Parenteral AC alone	185 (26.6%)	160 (29.4%)	6 (20.0%)	19 (15.8%)	
Parenteral AC + warfarin	145 (20.9%)	83 (15.2%)	4 (13.3%)	58 (48.3%)	
Warfarin	158 (22.7%)	138 (25.3%)	5 (16.7%)	15 (12.5%)	
DOAC	197 (28.3%)	154 (28.3%)	15 (50.0%)	28 (23.3%)	
Rivaroxaban	192 (97.5%)	151 (98.1%)	14 (93.3%)	27 (96.4%)	
Dabigatran	2 (1.0%)	0	1 (6.7%)	1 (3.6%)	
Apixaban	3 (1.5%)	3 (2.0%)	0	0	
Not Documented	10 (1.4%)	10 (1.8%)	0	0	
PE and PE+DVT					<0.0001
Parenteral AC alone	146 (25.3%)	129 (28.0%)	5 (26.3%)	12 (12.4%)	
Parenteral AC + warfarin	129 (22.4%)	77 (16.7%)	1 (5.3%)	51 (52.6%)	
Warfarin	132 (22.9%)	119 (25.8%)	2 (10.5%)	11 (11.3%)	
DOAC	161 (28.0%)	127 (27.6%)	11 (57.9%)	23 (23.7%)	
Rivaroxaban	156 (96.9%)	124 (97.6%)	10 (90.9%)	22 (95.6%)	
Dabigatran	2 (1.2%)	0	1 (9.1%)	1 (4.4%)	
Apixaban	3 (1.9%)	3 (2.4)	0	0	
Not Documented	8 (1.4%)	8 (1.7%)	0	0	
DVT alone					0.045
Parenteral AC alone	39 (32.8%)	31 (36.5%)	1 (9.1%)	7 (30.4%)	
Parenteral AC + warfarin	16 (13.4%)	6 (7.1%)	3 (2.7%)	7 (30.4%)	
Warfarin	26 (21.8%)	19 (22.4%)	3 (27.3%)	4 (17.4%)	
DOAC	36 (30.3%)	27 (31.8%)	4 (36.4%)	5 (21.7%)	
Rivaroxaban	36 (100%)	27 (100.0%)	4 (100.0%)	5 (100.0%)	
Dabigatran	0	0	0	0	
Apixaban	0	0	0	0	
Not Documented	2 (1.7%)	2 (2.4%)	0	0	
Follow-Up					
Family Doctor	358 (51.5%)	276 (50.6%)	20 (66.7%)	62 (51.7%)	
VTE Clinic	202 (29.1%)	201 (36.9%)	1 (3.3%)	0	
Specialist	124 (17.8%)	58 (10.6%)	3 (10.0%)	63 (52.5%)	
Anticoagulation Clinic	34 (4.9%)	10 (1.8%)	0	24 (20.0%)	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Return to ED	10 (1.4%)	8 (1.5%)	2 (6.7%)	0	
Other	101 (14.5%)	90 (16.5%)	6 (20.0%)	5 (4.2%)	
Not documented	41 (5.9%)	33 (6.1%)	2 (6.7%)	6 (5.0%)	

VTE=Venous Thromboembolism; PE=Pulmonary Embolism; DVT=Deep Vein Thrombosis; DOAC=Direct Oral Anticoagulant; AC=Anticoagulant; ED=Emergency Department

For peer review only


Table 3: Length of Stay in Days (Median, IQR) Based on Therapy

Therapy	All	Edmonton	Rural Alberta	Regina
DOAC	4 (2.0, 9.0)	4 (2.0, 8.0)	6 (2.0, 19.0)	4.5 (2.0, 8.5)
Parenteral Alone	5 (3.0, 10.0)	5 (2.0, 9.0)	15 (5.0, 21.0)	6 (4.0, 10.0)
Parenteral + Warfarin / Warfarin alone	7 (4.0, 12.0)	8 (4.0, 14.0)	4 (2.0, 6.0)	7 (4.0, 9.0)
P Value	<0.0001	<0.0001	0.091	0.223

DOAC=Direct Oral Anticoagulant

For peer review only

Figure 1: Patient Flow



214x110mm (96 x 96 DPI)

review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cohort studies

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6-7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	7
Study size	10	Explain how the study size was arrived at	NA-full year of data
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	7
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8, Figure 1
		(b) Give reasons for non-participation at each stage	8, Figure 1
		(c) Consider use of a flow diagram	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8, Table 1
		(b) Indicate number of participants with missing data for each variable of interest	Table 1
		(c) Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	Report numbers of outcome events or summary measures over time	8-9
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	NA
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9
Discussion			
Key results	18	Summarise key results with reference to study objectives	9-10
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	4

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Management of Acute Venous Thromboembolism Amongst a Cohort of Patients Discharged from Urban and Rural Hospitals

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022065.R1
Article Type:	Research
Date Submitted by the Author:	11-Jul-2018
Complete List of Authors:	Bungard, Tammy; University of Alberta Hospital, Medicine Ritchie, Bruce; University of Alberta Faculty of Medicine and Dentistry, Hematology Bolt, Jennifer; Interior Health Authority, Senior's Health and Awareness Semchuk, William; Regina Qu'Appelle Health Region, Pharmacy Services
Primary Subject Heading:	Haematology (incl blood transfusion)
Secondary Subject Heading:	Health services research
Keywords:	Anticoagulation < HAEMATOLOGY, Clinical audit < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Thromboembolism < CARDIOLOGY

SCHOLARONE™
Manuscripts

Management of Acute Venous Thromboembolism Amongst a Cohort of Patients Discharged from Urban and Rural Hospitals

Tammy J Bungard, BSP, PharmD*
Associate Professor of Medicine, Division of Cardiology
University of Alberta, Edmonton, Alberta

Bruce Ritchie, MD, FRCP(C)
Professor of Medicine, Division of Hematology
University of Alberta, Edmonton, Alberta
britchie@ualberta.ca

Jennifer Bolt, BScPharm, PharmD
When work was conducted: Residency and Education Coordinator, Pharmacy Services
Regina Qu'Appelle Health Region, Regina, Saskatchewan
Current: Clinical Pharmacy Specialist, Interior Health Authority
Kelowna, British Columbia
Jennifer.Bolt@interiorhealth.ca

William Semchuk, BSP, MSc, PharmD, FCSHP
Manager, Clinical Pharmacy Services,
Regina Qu'Appelle Health Region, Regina, Saskatchewan
Bill.Semchuk@rqhealth.ca

Text Word Count: 2,692

*Corresponding Author:

Dr. Tammy J Bungard
EPICORE Centre
362 Heritage Medical Research Centre
University of Alberta
Edmonton, AB T6G 2S2
Email: tammy.bungard@ualberta.ca
Phone: 780-492-3431 Fax: 780-492-6059

ABSTRACT:

Objective: To determine anticoagulant therapy at hospital discharge for patients with acute venous thromboembolism (VTE) and secondarily, to describe factors affecting choice of therapy.

Design: A retrospective chart review.

Setting: Canadian hospitals in Edmonton, Alberta (N=4), Regina, Saskatchewan (N=2) and rural Alberta (N=3) from April 2014 to March 2015.

Participants: All patients discharged with an acute VTE were screened. Those with atypical clots, another indication for anticoagulation, pregnancy/breastfeeding or lifespan < 3 months were excluded.

Interventions: None.

Primary and secondary outcomes: Primarily, we identified the proportion of patients discharged from hospital with acute VTE that were prescribed either traditional therapy (parenteral anticoagulant \pm warfarin) or a direct acting oral anticoagulant (DOAC). Secondarily, management based on setting, therapy choice based on DVT versus PE, clot burden and renal function was compared. DOAC dosing was assessed (when prescribed), length of hospital stay based on therapy was compared, and planned follow-up in the community was described.

Results: Amongst the 695 patients included, most were discharged following a diagnosis of PE (82.9%) on traditional therapy (parenteral anticoagulant +/- warfarin) (70.2%) with follow-up by either a family doctor (51.5%) or specialist/clinic (46.9%) post-discharge. Regional variation was most evident between urban and rural sites. Of those prescribed a DOAC (28.3%), the majority were dosed appropriately (85.8%). DOAC use did not differ between those with DVT and PE, was proportionately higher for less severe clots, and declined with worsening renal function. Patients prescribed DOACs vs traditional therapy had shorter length of stays (4 versus 7 days, respectively).

1
2
3 **Conclusions:** Uptake of DOAC therapy for acute VTE was modest and may have been influenced by the
4 timing of the audit in relation to the approval of these agents for this indication. Future audits should
5 occur to assess temporal changes and ongoing appropriateness of care delivery.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This study consists of a large cohort of patients discharged with acute DVT or PE from 2 urban areas and 3 rural sites throughout an entire year, thereby providing a good reflection of practice patterns.
- All patient charts were reviewed for inclusion, thereby enabling accurate data capture of the acute VTE population.
- Although this audit occurred early in the licensing of DOACs for VTE, these data offer a benchmark for future usage as guidelines more aggressively incorporate the utilization of DOACs in this population.
- Given our study design, we were not able to collect data for patients following discharge from hospital, thereby prohibiting the assessment of patient outcomes.

FUNDING STATEMENT

Funding was received from Pfizer Canada (via Dr. Bungard) in the form of an unrestricted grant. The sponsor had no role in the protocol design, study conduct, analysis/interpretation of the findings or decision to publish.

COMPETING INTEREST STATEMENT

TJB has received honoraria for an advisory board for BMS-Pfizer and Boehringer Ingelheim, as well as honoraria for speaking from Bayer. TJB has received unrestricted grants from Pfizer, Bayer and Leo Pharma. BR has served on advisory boards, given sponsored lectures using his own slides and received travel expense remuneration for Bayer, Baxter, Boehringer-Ingelheim, CSL-Behring, Pfizer, Sanofi, Servier and Shire. In lieu of honoraria for these activities, the companies have given financial contributions to the University of Alberta. BR reports grants from Novo Nordisk, CSL-Behring and Baxter, all outside of this submitted work. JB has received speaker honoraria from Boehringer Ingelheim in the

1
2
3 past two years. WS has received honoraria from Bayer, Pfizer, Bristol Myers Squibb and Boehringer
4
5 Ingleheim. He has served as a consultant or on an Advisory Board for Bayer and Pfizer/Bristol Myers
6
7 Squibb and he has received an unrestricted research grant from Pfizer.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

INTRODUCTION

After over half a century of vitamin K antagonists as the only available oral anticoagulant therapy, several direct oral anticoagulants (DOACs) have been approved within the past 5 years for the acute treatment of venous thromboembolism (VTE).¹⁻⁴ Large scale trials have reported non-inferiority for efficacy and similar (or improved) rates of major bleeding with the DOACs relative to traditional therapy.⁵⁻¹⁰ Moreover, the DOACs (rivaroxaban, dabigatran, apixaban and edoxaban) offer advantages over the traditional therapy of an injectable anticoagulant (typically low molecular weight heparin [LMWH]) overlapped with warfarin.¹¹ Unlike warfarin therapy, all DOACs have standardized dosing regimens that lack the need for routine coagulation monitoring and offer a therapeutic effect within hours of administration. Rivaroxaban and apixaban do not require initial therapy with an injectable anticoagulant, further streamlining care delivery.

While guidelines in 2012¹² recommended the management of deep vein thrombosis (DVT) on an outpatient basis, only more recent guidelines (2016)¹³ suggest the management of those with a low risk pulmonary embolism (PE) at home or following a short length of stay in hospital. With both changing recommendations for managing DVT/PE alongside the emergence of new and more streamlined anticoagulant options, patterns of practices for managing VTE amongst those discharged from hospital across both urban and rural sites has not been well characterized in the literature. As such, amongst a cohort of patients discharged from hospital with acute VTE, we hypothesized a modest early adoption of DOACs across both urban and rural sites in preference to traditional therapies, with DOAC uptake anticipated to be most prevalent in those with less severe clots.

METHODS

Data Sources

For each institution, medical records were retrieved and reviewed by trained data abstractors (2 for Alberta-based sites and 1 for Regina-sites). All data elements (demographics, DVT vs PE,

1
2
3 anticoagulant prescribed at discharge and follow-up plan in the community) were extracted as per the
4 documentation in the hospital-based and directly entered into the research electronic data capture
5 (REDCap) program. As this was a retrospective chart review, missing data elements (such as weight)
6
7 were identified and reported, accordingly.
8
9
10

11 **Study Setting**

12 Reflective of a collaboration of local investigators, this retrospective chart review was conducted
13
14 at the 4 largest hospitals in Edmonton, Alberta (University of Alberta Hospital, Royal Alexandra Hospital,
15
16 Misericordia Hospital, Grey Nuns Hospital), 3 rural hospitals in Alberta (Wetaskiwin Hospital, Westlock
17
18 Healthcare Centre and Athabasca Healthcare Centre) and the 2 hospitals in Regina, Saskatchewan
19
20 (Regina General Hospital and Pasqua Hospital). Given that Alberta and Saskatchewan are 2 neighboring
21
22 provinces in Canada having different health authorities with different geographic distributions, data for
23
24 the urban sites of Edmonton and Regina were kept separate and compared, accordingly.
25
26
27
28
29

30 **Patient Population**

31 All patients with a discharge diagnosis of deep vein thrombosis (DVT) (ICD-10 code I82 + sub-
32
33 indices) or pulmonary embolism (PE) (ICD-10 code I26 + sub-indices) between April 1, 2014 and March
34
35 31, 2015 were screened. Atypical clot locations (e.g., axillary/subclavian veins, portal vein) were not
36
37 included given their lack of enrollment in the large scale non-inferiority trials of the DOACs.⁵⁻¹⁰ Patients
38
39 were also excluded if they had another indication for therapeutic anticoagulation (e.g., mechanical heart
40
41 valve, atrial fibrillation), were not discharged alive, had an anticipated lifespan < 3 months
42
43 (documentation of palliation or prognosis), were < 18 years of age, were discharged directly from the
44
45 emergency department or were pregnant or breastfeeding.
46
47
48
49

50 **Outcomes**

51 Primarily, we sought to determine the proportion of patients discharged from hospital with
52
53 acute VTE that were prescribed a traditional therapy (parenteral anticoagulant ± warfarin) or a DOAC.
54
55
56
57
58
59

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Secondarily, we sought to compare differences in management between those in the Edmonton area, Regina area and rural Alberta. Use of DOACs for PE versus DVT was compared, as well as whether clot burden influenced anticoagulant selection. DVT was classified as proximal (at or above the popliteal vein) or distal in the leg. For PE, the validated simplified Pulmonary Embolism Severity Indices (sPESI) of either 0 or ≥ 1 was used, calculated at the time of presentation of the PE.^{14,15}

When prescribed, the use of DOACs was assessed for concordance with dosing regimens with Health Canada approved product monographs as per prescriptions received both in hospital and as planned at the point of discharge.¹⁻⁴ DOAC dosing was considered concordant if therapy was provided with either a parenteral anticoagulant or the appropriate up front (larger dose) of rivaroxaban (15mg BID) or apixaban (10mg BID) for the appropriate duration (3 and 1 week, respectively). We also assessed the difference in length of hospital stay in patients prescribed a DOAC versus a traditional therapy, and with whom follow-up was to occur after discharge.

Notably, these data represent a detailed evaluation specific to patients hospitalized with acute VTE. Our audit also encompassed the cohort of patients discharged directly from emergency departments from all institutions. As per our pre-planned analysis, there are 2 other manuscripts under review; one detailing the emergency department cohort and the other comparing (in aggregate amongst the urban settings) patents discharged directly from the emergency department versus those hospitalized.^{16,17}

Patient and Public Involvement Statement

Patients and or the public were not involved in this study.

Analysis

Data analysis was performed at the Epidemiology Coordinating and Research (EPICORE) Centre. All data is contained within REDCap, University of Alberta, and are available to the principal investigator (TJB). No data sharing agreement is in place. Data were collated and reported based on location, namely

1
2
3 Edmonton area, Regina area and rural Alberta. Patients' characteristics were compared between sites
4 using mean (SD) or median (IQR) as appropriate for the continuous data and proportions (%) for
5
6
7 categorical data. Chi-square test was used to compare discharge therapies between sites and different
8
9
10 groups. Statistical analysis was carried out on SAS version 9.4. Health Research Ethics Board approval
11
12 was received through the University of Alberta (Pro00056384) for all Alberta sites, and via the Regina
13
14 Qu'Appelle Health Region (REB 15-65) for the Regina sites.

16 RESULTS

17
18
19 A total of 958 charts were screened with 695 (72.5%) included (Figure 1). The most common
20
21 reasons for exclusion were lack of an acute VTE diagnosis (39.9%) and another indication for therapeutic
22
23 anticoagulation (23.6%). Overall, those included had an average age (\pm SD) of 63.3 ± 17.3 years, a median
24
25 body weight of 85.5Kg and only a minority (3.5%) had a creatinine clearance (CrCl) <30 mL/min (Table 1).
26
27 The majority of patients had PE (82.9%), particularly in the urban centres of Edmonton (84.4%) and
28
29 Regina (80.8%), while the diagnosis of PE was lower in rural Alberta (63.3%). Based on the sPESI score,
30
31 the majority with PE in Edmonton (66.5%) and Regina (58.8%) had a PESI score ≥ 1 , while rural Alberta
32
33 was nearly half the patients (47.4%). The majority of patients admitted for DVT had a proximal clot;
34
35 Edmonton (87.1%), rural Alberta (81.8%), Regina (69.6%). Of note, full leg ultrasounds were utilized in
36
37 Regina while only above the knee ultrasounds were utilized in both Edmonton and rural Alberta.
38
39

40
41 The majority of patients (70.2%) were discharged from hospital on a traditional therapy
42
43 (parenteral anticoagulant +/- warfarin), with 28.3% receiving a DOAC (Table 2). Notably, Regina had the
44
45 highest rate of a warfarin-based regimen (60.8%), with less warfarin used in Edmonton (40.5%) and rural
46
47 Alberta (30%). Use of DOACs was most common in rural Alberta (57.9%), followed by Edmonton (28.3%)
48
49 and Regina (23.3%).
50

51
52 There was no difference in proportionate use of a DOAC for PE compared to DVT (28.0% and
53
54 30.3%, respectively; $P=0.61$). Patients having a sPESI score of 0 were more likely to be prescribed a
55
56

DOAC relative to those with a score ≥ 1 (33.3% and 24.3%, respectively; $P < 0.0001$). Only a small portion of patients in our study had distal DVTs (N=13) compared with proximal DVTs (N=99), and DOAC use was not significantly different for distal DVTs (50%) compared to proximal DVTs (27.6%) ($P = 0.14$).

Amongst the 197 patients prescribed a DOAC, the majority (97.5%) received rivaroxaban, with a minority of patients receiving apixaban (N=3 [1.5%]) and dabigatran (N=2 [1.0%]). DOAC dosing for the acute treatment of VTE was consistent with product monographs in 85.8% of patients. The majority of inconsistent dosing with rivaroxaban was attributable to not having a full 3 weeks of therapy of higher dose (rivaroxaban 15mg BID) prior to implementing the lower maintenance dose of 20mg daily (N=25/28). Only a minority of patients had renal dysfunction with a CrCl < 30 mL/min (N=23 [3.5%]). DOAC use declined with worsening renal function with 31.1% (161/517), 19.0% (23/121), and 4.4% (1/23) prescribed a DOAC with a CrCl > 50 , 30-50 and < 30 mL/min, respectively ($P < 0.0001$).

Combining all sites, median (IQR) length of stay was shortest amongst those prescribed a DOAC (4 days [2.0, 9.0]) and longest for those transitioning from LMWH to warfarin therapy (7 days [4.0, 12.0]) ($P < 0.0001$) (Table 3). At discharge, amongst the urban sites follow-up was to occur most commonly with a VTE clinic/specialist (47.5% for Edmonton and 52.5% with Regina) whereas rural Alberta referred most to family doctors (66.7%) (Table 2).

DISCUSSION

Amongst all sites, the majority (70.2%) of patients presenting with acute VTE were prescribed traditional therapies (parenteral anticoagulant +/- warfarin) at hospital discharge, and 28.3% received a DOAC. Rural Alberta had the greatest uptake of the DOACs (50%), followed by the Edmonton area (28.3%) and Regina area (23.3%). Uptake of DOACs in rural Alberta is likely attributable to many factors, including more limited laboratory availability for routine coagulation testing, primary care physicians providing care within the hospital and hospital pharmacists who were comfortable with data pertaining to the use of DOACs in this population. While we found no difference in the use of DOACs for PE relative

1
2
3 to DVT, DOACs were used more in patients with lower risk PE and normal renal function. When
4 prescribed, the majority of DOAC use (85.8%) was concordant with Canadian product labeling.
5
6

7 Our overall rate of DOAC use for acute VTE (28.3%) is similar to that reported amongst 328
8 patients discharged from Florence, Italy hospitals following acute PE (32.5%) during 2014 and 2015.¹⁸
9
10 These investigators assessed a time interval that partially overlapped with ours, and report an increase
11 in DOAC use from 2014 (23.2%) to 2015 (40.1%). A single site evaluation of therapy for an incident VTE
12 presentation amongst 256 patients in Montreal, Quebec Canada in 2013 found similar overall trends to
13 our study with most patients being treated with warfarin (54.7%) followed by LMWH alone (27.7%) and
14 rivaroxaban (17.6%).¹⁹ Unlike our study, those in the Quebec evaluation with DVT (N=94) were more
15 likely than those with PE (N=162) to receive rivaroxaban (28.7% and 11.1%, respectively). In terms of
16 clinical presentation of PE, a single site evaluation of 39 patients with PE being discharged from hospital
17 on a DOAC showed more use amongst those defined as low risk (83%), with overall DOAC use still being
18 high for those at intermediate-low risk (40%), intermediate-high risk (68%) and high risk (40%).¹⁸ Our
19 study found similar results in that more patients with a sPESI score of 0 (33.3%) received DOACs,
20 however DOACs were still used amongst those with a score of ≥ 1 (24.3%).
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 Concordance with dosing for acute VTE in our study (85.8%) was similar to that reported in an
38 audit assessing the appropriateness of DOAC prescribing amongst 39 VTE patients in Australia (84.6%)²⁰
39 and lower than that reported in a non-interventional study assessing the use of the appropriate initial
40 dosing of rivaroxaban (93.7%).²¹ Unlike our study wherein the majority of patients not receiving DOAC
41 dosing per the product monographs due to not receiving the appropriate up front rivaroxaban 15mg
42 BID, the non-interventional study reported that only 73% of patients went onto step down to
43 rivaroxaban 20mg daily.²¹ Unfortunately, we were not able to identify therapy changes beyond that
44 planned at hospital discharge within our study.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Given that initial therapy with an injectable anticoagulant is not required for both rivaroxaban
4 and apixaban and that routine coagulation monitoring is not performed with all of the DOACs, care
5 delivery with a DOACs compared to traditional therapy with a parenteral anticoagulant ± warfarin
6 should be simplified. Data from the North American cohort of patients enrolled in landmark trials
7 reports a significantly shorter length of stay for those receiving rivaroxaban (3.0 days [3.0-5.0])
8 compared to traditional therapy (4.0 days [3.0-6.0]; P=0.0004).²² A single site evaluation in Quebec,
9 Canada affirmed the clinical trial data, and reported median length of stay to be shorter with
10 rivaroxaban use (3.5 days) relative to LMWH alone or warfarin therapy (6 days).¹⁹ Similarly, a single
11 American institution identified those discharged on rivaroxaban compared to warfarin had shorter
12 hospital stays (3.5 and 7 days, respectively; P<0.001).²³ While we did not set out to discern other factors
13 that may have impacted length of hospital stay, our data is consistent with these,^{19,22,23} as patients
14 receiving a DOAC had a shorter median length of stay (Table 3).
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **STRENGTHS AND LIMITATIONS**

31
32 Herein we present a large cohort of patients with acute VTE being discharged following
33 hospitalization. For all sites, we reviewed all medical records with a discharge diagnosis of deep vein
34 thrombosis (DVT) (ICD-10 code I82 + sub-indices) or pulmonary embolism (PE) (ICD-10 code I26 + sub-
35 indices) over the span of a full year (April 2014 to March 2015). In doing so, different sample sizes were
36 identified from each area, with rural Alberta and Regina having fewer patients (N=30 and N=120,
37 respectively) than the Edmonton area (N=545). Despite the differences in sample sizes, these data
38 reflect local practices given the geographic populations and catchment areas (Edmonton: 1,328,290 plus
39 catchment of ~500,000; Regina: 230,020 plus catchment of 500,000; rural Alberta 3 sites: 30,065) and
40 that an entire year was assessed.²⁴⁻²⁸ The timing of our audit is reflective of the early uptake of DOACs
41 for the acute treatment of VTE given only rivaroxaban had Health Canada approval throughout the
42 entire time interval audited and that prescribing patterns may have changed beyond the timing of the
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 audit (March 2015). Despite this, we identified reasonable uptake of the DOACs (28.3%), with use that
4
5 complied with product monograph labeling in the vast majority (85.8%). This data can serve as a marker
6
7 for future analyses wherein usage can be compared to assess the uptake of this therapeutic approach
8
9 over time as guidelines more aggressively incorporate the utilization of DOACs in this population and
10
11 clinicians become more comfortable with their use.
12
13

14 Our design (retrospective medical record review) was selected to allow us to accurately select
15
16 patients with acute VTE to ascertain practice patterns. Given the diverse geography and volume of
17
18 records to review, 3 data abstractors were necessary. A master key defining eligibility, data points to
19
20 collect and how to code variables in REDCap was used. Within REDCap, restrictions for variables were
21
22 programmed to minimize data entry error. Prior to finishing data collection at each site, quality
23
24 assurance reports were performed to ensure accuracy of data. As this was a record review, we were
25
26 limited only to information available in the hospital-based chart. Given this, some data elements were
27
28 not documented (e.g., weight, serum creatinine), leaving us to report data for those available.
29
30 Moreover, our design did not enable us to collect data following hospital discharge, limiting us from
31
32 determining if patients got their prescriptions filled or had complications following discharge.
33
34
35

36 37 **CONCLUSION**

38
39 In summary, we report the management of a large cohort of acute VTE patients being
40
41 discharged from hospitals within Canada. Over a time interval early in the approval process for DOACs
42
43 for the acute treatment of VTE, we report a modest uptake of DOACs (28.3%) that were, overall, dosed
44
45 correctly for the majority of patients (85.8%). Variation in therapies used was evident with the most
46
47 common regimen being warfarin-based in Regina (60.7%) and Edmonton (40.5%) and a DOAC in rural
48
49 Alberta (50.5%). Use of rivaroxaban was proportionately higher for less severe clots, and those
50
51 prescribed a DOAC had a shorter length of stay relative to those given traditional therapies. As time
52
53 evolves, it is anticipated use of DOACs will increase for the management of VTE. Practitioners and health
54
55
56
57
58
59
60

1
2
3 delivery systems should continue to consider the opportunity provided by the DOACs to simplify and
4 shorten hospital based care as further data emerges to support their place in therapy. Future
5
6 evaluations should occur to assess temporal changes, ongoing appropriateness of care delivery and the
7
8 impact that DOACs may have on healthcare system resource allocation.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

REFERENCES

1. Pfizer Canada Inc, Kirkland, Quebec and Bristol-Myers Squibb Canada, Montreal, Quebec. Eliquis™ Product Monograph. Montreal, Quebec.
http://www.pfizer.ca/sites/g/files/g10028126/f/201607/ELIQUIS_PM_184464_16June2016_E_mar_keted.pdf Accessed 9 February 2017
2. Daiichi Sankyo, Inc, Parsippany, NJ, USA (Manufacturer); Progress Therapeutics, Newmarket, Ontario (Importer and Distributer). Lixiana™ Product Monograph.
https://pdf.hres.ca/dpd_pm/00037831.PDF Accessed 9 February 2017
3. Boehringer Ingelheim Canada Ltd. Pradaxa™ Product Monograph, Burlington, Ontario.
<https://www.boehringer-ingelheim.ca/sites/ca/files/documents/pradaxapmen.pdf> Accessed 9 February 2017
4. Bayer Inc. Xarelto™ Product Monograph. Toronto, Ontario. Available:
<http://omr.bayer.ca/omr/online/xarelto-pm-en.pdf> Accessed 9 February 2017
5. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M et al for the AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. *N Engl J Med* 2013;369:799-808. doi: 10.1056/NEJMoa1302507
6. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H et al for the RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. *N Engl J Med* 2009;361:2342-52. doi: 10.1056/NEJMoa0906598
7. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Erikson H, Mismetti P et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. *Circ* 2014;129:764-772. doi: 10.1161/CIRCULATIONAHA.113.004450
8. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. *N Engl J Med* 2010;363:2499-510. doi:10.1056/NEJMoa1007903

- 1
2
3 9. The EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary
4 embolism. *N Engl J Med* 2012;366:1287-97. doi:10.1056/NEJMoa1113572
- 5
6
7 10. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous
8 thromboembolism. *N Engl J Med* 2013;369:1406-1415. doi: 10.1056/NEJMoa1306638
- 9
10
11 11. Finks SW, Trujillo TC, Dobesh PP (2016) Management of venous thromboembolism: recent
12 advances in oral anticoagulation therapy. *Ann Pharmacother* 50:486-501. doi:
13 10.1177/1060028016632785
- 14
15
16 12. Kearon C, Akl EA, Comerota AJ, Prandoni P et al. Antithrombotic therapy for VTE disease:
17 Antithrombotic therapy an dprevention of thrombosis, 9th ed: American Collete of Cheast
18 Physicians Evidence-based clinical practice guidelines. *CHEST* 2012;141:e419S-494S.
- 19
20
21 13. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H et al. Antithrombotic
22 therapy for VTE disease: CHEST guideline and expert panel report. *CHEST* 2016;149(2):315-
23 352.
- 24
25
26 14. Chan CM, Woods C, Shorr AF. The validation and reproducibility of the pulmonary embolism
27 severity index. *J Thromb Haemost* 2010;8:1509-1514. Doi: 10.1111/j.1538-7836.2010.03888.x.
- 28
29
30 15. Righini M, Roy PM, Meyer G, Verschuren F, Aujesky D, Le Gal G. The simplified pulmonary
31 embolism severity index (PESI): validation of a clinical prognostic model for pulmonary embolism. *J*
32 *Thromb Heamost* 2011;9:2001-2007. doi: 10.1111/j.1538-7836.2011.04469.x.
- 33
34
35 16. Bungard TJ, Ritchie B, Bolt J, Semchuk W. Management of acute venous thromboembolism amongst
36 a cohort of patients discharged directly from the emergency department. *BMJ Open*, Under
37 Review, February 2018.
- 38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 17. Bungard TJ, Ritchie B, Bolt J, Semchuk W. Anticoagulant therapies for acute venous
4 thromboembolism: A comparison between those discharged directly from the emergency
5 department versus hospitalized in 2 Canadian cities. *BMJ Open*, Under Review, February 2018.
6
7
8
9
10 18. Masotti L, Vannucchi V, Poggi M, Landini G. Trends in length of hospital stay in acute pulmonary
11 embolism over the years. What is changing in the era of direct oral anticoagulants? *J Cardiovasc*
12 *Med* 2015;17:817-823. doi: 10.2459/JCM.0000000000000356
13
14
15
16 19. Dault R, Vanasse A, Blais L, Perreault S, Farand P, Le Templier G et al. Patterns of predictors of use
17 of anticoagulants for the treatment of venous thromboembolism following approval of rivaroxaban.
18 *Clin Appl Thromb Hemost* 2016;22:765-771. doi: 10.1177/1076029615611249
19
20
21
22
23 20. Pattullo CS, Barras M, Tai B, McKean M, Donovan P. New oral anticoagulants: appropriateness of
24 prescribing in a real-world setting. *Int Med J* 2016;46:812-818. doi: 10.1111/imj.13118
25
26
27
28 21. Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J et al. Safety and effectiveness of
29 oral rivaroxaban versus standard anticoagulation for the symptomatic deep-vein thrombosis
30 (XALIA): an international, prospective, non-interventional study. *Lancet Haematol* 2016;3:e12-21.
31 doi: hggp://dx.doi.org/10.1016/S2353-3026(15)00257-4
32
33
34
35
36 22. Bookhart BK, Haskell L, Bamber L, Wang M, Schein J, Mody SH. Length of stay and economic
37 consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE:
38 findings from the North American EINSTEIN clinical trial program. *J Med Econ* 2014;17:1691-695.
39 doi: 10.3111/13696998.2014.946993
40
41
42
43
44
45 23. Desai A, Desai A, Calixte R, Aparnath M, Hindenburg A, Salzman S et al. Comparing length of stay
46 between patients taking rivaroxaban and conventional anticoagulants for treatment of venous
47 thromboembolism. *Lung* 2016;194:605-611. doi:10.1007/s00408-016-9898-8
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 24. Population of Edmonton area, accessed October 31, 2017:
4

5 [http://globalnews.ca/news/1824910/edmonton-region-has-canadas-2nd-highest-population-](http://globalnews.ca/news/1824910/edmonton-region-has-canadas-2nd-highest-population-growth-stats-canada/)
6 [growth-stats-canada/](http://globalnews.ca/news/1824910/edmonton-region-has-canadas-2nd-highest-population-growth-stats-canada/)
7
8

9
10 25. Population of Regina, accessed October 31, 2017:

11 <http://www.leaderpost.com/life/Regina+population+cracks/9553267/story.html>
12
13

14 26. Athabasca Population, accessed October 31, 2017: [http://www.city-data.com/canada/Athabasca-](http://www.city-data.com/canada/Athabasca-Town.html)
15 [Town.html](http://www.city-data.com/canada/Athabasca-Town.html)
16
17

18 27. Westlock Population, accessed October 31, 2017: [http://www.city-data.com/canada/Westlock-](http://www.city-data.com/canada/Westlock-Town.html)
19 [Town.html](http://www.city-data.com/canada/Westlock-Town.html)
20
21

22
23 28. Wetaskiwin Population, accessed October 31, 2017:

24 <https://www.wetaskiwin.ca/DocumentCenter/View/1039>
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DATA SHARING AGREEMENT

There is no data sharing agreement – this is included in the original research article.

AUTHOR CONTRIBUTIONS

TJB contributed to the design of the work, the acquisition, analysis and interpretation of the data. TJB drafted the original manuscript, approved the final version to be published and is accountable for all aspects of the work related to accuracy or integrity. BR contributed to the design of the work, the interpretation of the data and critically revised the manuscript. BR approved the final version to be published and is accountable for all aspects of the work related to accuracy or integrity. JB contributed to the acquisition and interpretation of the data, critically revised the manuscript and approved the final version to be published. JB is accountable for all aspects of the work related to accuracy or integrity. WS contributed to the design, acquisition and interpretation of the data, critically revised the manuscript and approved the final version to be published. WS is also accountable for the accuracy and integrity of this work.

Figure 1: Patient Flow

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Baseline Characteristics

	Total	Edmonton	Rural Alberta	Regina
Screened (N)	958	736	41	181
Included (N, %)	695 (72.5%)	545 (74.0%)	30 (73.2%)	120 (66.3%)
Male (N, %)	350 (50.4%)	282 (51.7%)	16 (53.3%)	52 (43.3%)
Mean age (mean \pm SD)	63.3 \pm 17.3	63.8 \pm 17.2	64.2 \pm 16.9	60.4 \pm 17.6
Weight Documented (N, %) ^a	680 (97.8%)	534 (98.0%)	28 (93.3%)	118 (98.3%)
Weight, Kg (Median, IQR)	85.5 (70.0, 106.0)	84.5 (70.0, 106.0)	84.3 (71.0, 98.3)	90.5 (70.0, 110.0)
CrCl Documented (N, %) ^a	661 (95.0%)	515 (94.5%)	29 (96.7%)	117 (97.5%)
< 30 mL/min	23 (3.5%)	20 (3.9%)	1 (3.5%)	2 (1.7%)
30-49 mL/min	121 (18.3%)	96 (18.6%)	3 (10.3%)	22 (18.8%)
> 50 mL/min	517 (78.2%)	399 (77.5%)	25 (86.2%)	93 (79.5%)
VTE				
DVT	119 (17.1%)	85 (15.6%)	11 (36.6%)	23 (19.2%)
Distal	13 (10.9%)	7 (8.2%)	0	6 (26.1%)
Proximal ^b	99 (83.2%)	74 (87.1%)	9 (81.8%)	16 (69.6%)
Not documented	7 (5.9%)	4 (4.7%)	2 (18.2%)	1 (4.3%)
PE and PE + DVT ^c	576 (82.9%)	460 (84.4%)	19 (63.3%)	97 (80.8%)
PE – Simplified PESI Score: ^d	567 (98.4%)	451 (98.0%)	19 (100%)	97 (100%)
0 point	201 (35.4%)	151 (33.5%)	10 (52.6%)	40 (41.2%)
\geq 1 points	366 (64.6%)	300 (66.5%)	9 (47.4%)	57 (58.8%)
History of:				
Cancer	158 (22.7%)	119 (21.8%)	10 (33.3%)	29 (24.2%)
Pulmonary disease	143 (20.6%)	114 (20.9%)	6 (20.0%)	23 (19.2%)
Prior VTE	100 (14.4%)	81 (14.9%)	6 (20.0%)	13 (10.8%)
Recent surgery	32 (4.6%)	23 (4.2%)	0	9 (7.5%)
Length of Stay (median, IQR)	6.0 (3.0, 11.0)	6.0 (3.0, 11.0)	5.5 (3.0, 13.0)	6.0 (3.0, 9.0)

CrCl=Creatinine Clearance; SD=Standard Deviation; IQR=Interquartile Range; PE=Pulmonary Embolism; DVT=Deep Vein Thrombosis; PESI=Pulmonary Embolism Severity Index; LOS=Length of Stay

^anot all patients had weight and serum creatinine documented in the chart

^bCombined popliteal, femoral, common femoral, and iliac

^ccombined PE with PE+DVT and report it all as PE

^dPESI score could not be calculated in 9 patients due to missing variable(s)

Table 2: Therapy at Discharge and Follow-Up Plan for Hospitalized Cohort

	Total	Edmonton	Rural Alberta	Regina	P Value
VTE (All Combined)					<0.0001
Parenteral AC alone	185 (26.6%)	160 (29.4%)	6 (20.0%)	19 (15.8%)	
Parenteral AC + warfarin	145 (20.9%)	83 (15.2%)	4 (13.3%)	58 (48.3%)	
Warfarin	158 (22.7%)	138 (25.3%)	5 (16.7%)	15 (12.5%)	
DOAC	197 (28.3%)	154 (28.3%)	15 (50.0%)	28 (23.3%)	
Rivaroxaban	192 (97.5%)	151 (98.1%)	14 (93.3%)	27 (96.4%)	
Dabigatran	2 (1.0%)	0	1 (6.7%)	1 (3.6%)	
Apixaban	3 (1.5%)	3 (2.0%)	0	0	
Not Documented	10 (1.4%)	10 (1.8%)	0	0	
PE and PE+DVT					<0.0001
Parenteral AC alone	146 (25.3%)	129 (28.0%)	5 (26.3%)	12 (12.4%)	
Parenteral AC + warfarin	129 (22.4%)	77 (16.7%)	1 (5.3%)	51 (52.6%)	
Warfarin	132 (22.9%)	119 (25.8%)	2 (10.5%)	11 (11.3%)	
DOAC	161 (28.0%)	127 (27.6%)	11 (57.9%)	23 (23.7%)	
Rivaroxaban	156 (96.9%)	124 (97.6%)	10 (90.9%)	22 (95.6%)	
Dabigatran	2 (1.2%)	0	1 (9.1%)	1 (4.4%)	
Apixaban	3 (1.9%)	3 (2.4)	0	0	
Not Documented	8 (1.4%)	8 (1.7%)	0	0	
DVT alone					0.045
Parenteral AC alone	39 (32.8%)	31 (36.5%)	1 (9.1%)	7 (30.4%)	
Parenteral AC + warfarin	16 (13.4%)	6 (7.1%)	3 (2.7%)	7 (30.4%)	
Warfarin	26 (21.8%)	19 (22.4%)	3 (27.3%)	4 (17.4%)	
DOAC	36 (30.3%)	27 (31.8%)	4 (36.4%)	5 (21.7%)	
Rivaroxaban	36 (100%)	27 (100.0%)	4 (100.0%)	5 (100.0%)	
Dabigatran	0	0	0	0	
Apixaban	0	0	0	0	
Not Documented	2 (1.7%)	2 (2.4%)	0	0	
Follow-Up					
Family Doctor	358 (51.5%)	276 (50.6%)	20 (66.7%)	62 (51.7%)	
VTE Clinic	202 (29.1%)	201 (36.9%)	1 (3.3%)	0	
Specialist	124 (17.8%)	58 (10.6%)	3 (10.0%)	63 (52.5%)	
Anticoagulation Clinic	34 (4.9%)	10 (1.8%)	0	24 (20.0%)	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Return to ED	10 (1.4%)	8 (1.5%)	2 (6.7%)	0	
Other	101 (14.5%)	90 (16.5%)	6 (20.0%)	5 (4.2%)	
Not documented	41 (5.9%)	33 (6.1%)	2 (6.7%)	6 (5.0%)	

VTE=Venous Thromboembolism; PE=Pulmonary Embolism; DVT=Deep Vein Thrombosis; DOAC=Direct Oral Anticoagulant; AC=Anticoagulant; ED=Emergency Department

For peer review only

Table 3: Length of Stay in Days (Median, IQR) Based on Therapy


Therapy	All	Edmonton	Rural Alberta	Regina
DOAC	4 (2.0, 9.0)	4 (2.0, 8.0)	6 (2.0, 19.0)	4.5 (2.0, 8.5)
Parenteral Alone	5 (3.0, 10.0)	5 (2.0, 9.0)	15 (5.0, 21.0)	6 (4.0, 10.0)
Parenteral + Warfarin / Warfarin alone	7 (4.0, 12.0)	8 (4.0, 14.0)	4 (2.0, 6.0)	7 (4.0, 9.0)
P Value	<0.0001	<0.0001	0.091	0.223

DOAC=Direct Oral Anticoagulant

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Patient Flow



165x95mm (300 x 300 DPI)

Review only

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6-7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	7
Study size	10	Explain how the study size was arrived at	NA-full year of data
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	7
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8, Figure 1
		(b) Give reasons for non-participation at each stage	8, Figure 1
		(c) Consider use of a flow diagram	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8, Table 1
		(b) Indicate number of participants with missing data for each variable of interest	Table 1
		(c) Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	Report numbers of outcome events or summary measures over time	8-9
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	NA
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9
Discussion			
Key results	18	Summarise key results with reference to study objectives	9-10
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	4

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Anticoagulant Therapies for Acute Venous Thromboembolism Amongst a Cohort of Patients Discharged from Canadian Urban and Rural Hospitals

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022065.R2
Article Type:	Research
Date Submitted by the Author:	23-Aug-2018
Complete List of Authors:	Bungard, Tammy; University of Alberta Hospital, Medicine Ritchie, Bruce; University of Alberta Faculty of Medicine and Dentistry, Hematology Bolt, Jennifer; Interior Health Authority, Senior's Health and Awareness Semchuk, William; Regina Qu'Appelle Health Region, Pharmacy Services
Primary Subject Heading:	Haematology (incl blood transfusion)
Secondary Subject Heading:	Health services research
Keywords:	Anticoagulation < HAEMATOLOGY, Clinical audit < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, Thromboembolism < CARDIOLOGY

SCHOLARONE™
Manuscripts

1
2
3 **Anticoagulant Therapies for Acute Venous Thromboembolism Amongst a Cohort of Patients**
4 **Discharged from Canadian Urban and Rural Hospitals**
5
6

7 Tammy J Bungard, BSP, PharmD*
8 Associate Professor of Medicine, Division of Cardiology
9 University of Alberta, Edmonton, Alberta
10

11 Bruce Ritchie, MD, FRCP(C)
12 Professor of Medicine, Division of Hematology
13 University of Alberta, Edmonton, Alberta
14 britchie@ualberta.ca
15

16
17 Jennifer Bolt, BScPharm, PharmD
18 When work was conducted: Residency and Education Coordinator, Pharmacy Services
19 Regina Qu'Appelle Health Region, Regina, Saskatchewan
20 Current: Clinical Pharmacy Specialist, Interior Health Authority
21 Kelowna, British Columbia
22 Jennifer.Bolt@interiorhealth.ca
23

24
25 William Semchuk, BSP, MSc, PharmD, FCSHP
26 Manager, Clinical Pharmacy Services,
27 Regina Qu'Appelle Health Region, Regina, Saskatchewan
28 Bill.Semchuk@rqhealth.ca
29

30 Text Word Count: 2,692
31

32
33 *Corresponding Author:
34 Dr. Tammy J Bungard
35 EPICORE Centre
36 362 Heritage Medical Research Centre
37 University of Alberta
38 Edmonton, AB T6G 2S2
39 Email: tammy.bungard@ualberta.ca
40 Phone: 780-492-3431 Fax: 780-492-6059
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT:

Objective: To determine anticoagulant therapy at hospital discharge for patients with acute venous thromboembolism (VTE) and secondarily, to describe factors affecting choice of therapy.

Design: A retrospective chart review.

Setting: Canadian hospitals in Edmonton, Alberta (N=4), Regina, Saskatchewan (N=2) and rural Alberta (N=3) from April 2014 to March 2015.

Participants: All patients discharged with an acute VTE were screened. Those with atypical clots, another indication for anticoagulation, pregnancy/breastfeeding or lifespan < 3 months were excluded.

Interventions: None.

Primary and secondary outcomes: Primarily, we identified the proportion of patients discharged from hospital with acute VTE that were prescribed either traditional therapy (parenteral anticoagulant \pm warfarin) or a direct acting oral anticoagulant (DOAC). Secondarily, management based on setting, therapy choice based on DVT versus PE, clot burden and renal function was compared. DOAC dosing was assessed (when prescribed), length of hospital stay based on therapy was compared, and planned follow-up in the community was described.

Results: Amongst the 695 patients included, most were discharged following a diagnosis of PE (82.9%) on traditional therapy (parenteral anticoagulant +/- warfarin) (70.2%) with follow-up by either a family doctor (51.5%) or specialist/clinic (46.9%) post-discharge. Regional variation was most evident between urban and rural sites. Of those prescribed a DOAC (28.3%), the majority were dosed appropriately (85.8%). DOAC use did not differ between those with DVT and PE, was proportionately higher for less severe clots, and declined with worsening renal function. Patients prescribed DOACs vs traditional therapy had shorter length of stays (4 versus 7 days, respectively).

1
2
3 **Conclusions:** Uptake of DOAC therapy for acute VTE was modest and may have been influenced by the
4 timing of the audit in relation to the approval of these agents for this indication. Future audits should
5 occur to assess temporal changes and ongoing appropriateness of care delivery.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

STRENGTHS AND LIMITATIONS OF THIS STUDY

- This study consists of a large cohort of patients discharged with acute DVT or PE from 2 urban areas and 3 rural sites throughout an entire year, thereby providing a good reflection of practice patterns.
- All patient charts were reviewed for inclusion, thereby enabling accurate data capture of the acute VTE population.
- Although this audit occurred early in the licensing of DOACs for VTE, these data offer a benchmark for future usage as guidelines more aggressively incorporate the utilization of DOACs in this population.
- Given our study design, we were not able to collect data for patients following discharge from hospital, thereby prohibiting the assessment of patient outcomes.

FUNDING STATEMENT

Funding was received from Pfizer Canada (via Dr. Bungard) in the form of an unrestricted grant. The sponsor had no role in the protocol design, study conduct, analysis/interpretation of the findings or decision to publish.

COMPETING INTEREST STATEMENT

TJB has received honoraria for an advisory board for BMS-Pfizer and Boehringer Ingelheim, as well as honoraria for speaking from Bayer. TJB has received unrestricted grants from Pfizer, Bayer and Leo Pharma. BR has served on advisory boards, given sponsored lectures using his own slides and received travel expense remuneration for Bayer, Baxter, Boehringer-Ingelheim, CSL-Behring, Pfizer, Sanofi, Servier and Shire. In lieu of honoraria for these activities, the companies have given financial contributions to the University of Alberta. BR reports grants from Novo Nordisk, CSL-Behring and Baxter, all outside of this submitted work. JB has received speaker honoraria from Boehringer Ingelheim in the

1
2
3 past two years. WS has received honoraria from Bayer, Pfizer, Bristol Myers Squibb and Boehringer
4
5 Ingleheim. He has served as a consultant or on an Advisory Board for Bayer and Pfizer/Bristol Myers
6
7 Squibb and he has received an unrestricted research grant from Pfizer.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

INTRODUCTION

After over half a century of vitamin K antagonists as the only available oral anticoagulant therapy, several direct oral anticoagulants (DOACs) have been approved within the past 5 years for the acute treatment of venous thromboembolism (VTE).¹⁻⁴ Large scale trials have reported non-inferiority for efficacy and similar (or improved) rates of major bleeding with the DOACs relative to traditional therapy.⁵⁻¹⁰ Moreover, the DOACs (rivaroxaban, dabigatran, apixaban and edoxaban) offer advantages over the traditional therapy of an injectable anticoagulant (typically low molecular weight heparin [LMWH]) overlapped with warfarin.¹¹ Unlike warfarin therapy, all DOACs have standardized dosing regimens that lack the need for routine coagulation monitoring and offer a therapeutic effect within hours of administration. Rivaroxaban and apixaban do not require initial therapy with an injectable anticoagulant, further streamlining care delivery.

While guidelines in 2012¹² recommended the management of deep vein thrombosis (DVT) on an outpatient basis, only more recent guidelines (2016)¹³ suggest the management of those with a low risk pulmonary embolism (PE) at home or following a short length of stay in hospital. With both changing recommendations for managing DVT/PE alongside the emergence of new and more streamlined anticoagulant options, patterns of practices for managing VTE amongst those discharged from hospital across both urban and rural sites has not been well characterized in the literature. As such, amongst a cohort of patients discharged from hospital with acute VTE, we hypothesized a modest early adoption of DOACs across both urban and rural sites in preference to traditional therapies, with DOAC uptake anticipated to be most prevalent in those with less severe clots.

METHODS

Data Sources

For each institution, medical records were retrieved and reviewed by trained data abstractors (2 for Alberta-based sites and 1 for Regina-sites). All data elements (demographics, DVT vs PE,

1
2
3 anticoagulant prescribed at discharge and follow-up plan in the community) were extracted as per the
4 documentation in the hospital-based record and directly entered into the research electronic data
5 capture (REDCap) program. As this was a retrospective chart review, missing data elements (such as
6 weight) were identified and reported, accordingly.
7
8
9
10

11 **Study Setting**

12 Reflective of a collaboration of local investigators, this retrospective chart review was conducted
13 at the 4 largest hospitals in Edmonton, Alberta (University of Alberta Hospital, Royal Alexandra Hospital,
14 Misericordia Hospital, Grey Nuns Hospital), 3 rural hospitals in Alberta (Wetaskiwin Hospital, Westlock
15 Healthcare Centre and Athabasca Healthcare Centre) and the 2 hospitals in Regina, Saskatchewan
16 (Regina General Hospital and Pasqua Hospital). Given that Alberta and Saskatchewan are 2 neighboring
17 provinces in Canada having different health authorities with different geographic distributions, data for
18 the urban sites of Edmonton and Regina were kept separate and compared, accordingly.
19
20
21
22
23
24
25
26
27
28
29

30 **Patient Population**

31 All patients with a discharge diagnosis of deep vein thrombosis (DVT) (ICD-10 code I82 + sub-
32 indices) or pulmonary embolism (PE) (ICD-10 code I26 + sub-indices) between April 1, 2014 and March
33 31, 2015 were screened. Atypical clot locations (e.g., axillary/subclavian veins, portal vein) were not
34 included given their lack of enrollment in the large scale non-inferiority trials of the DOACs.⁵⁻¹⁰ Patients
35 were also excluded if they had another indication for therapeutic anticoagulation (e.g., mechanical heart
36 valve, atrial fibrillation), were not discharged alive, had an anticipated lifespan < 3 months
37 (documentation of palliation or prognosis), were < 18 years of age, were discharged directly from the
38 emergency department or were pregnant or breastfeeding.
39
40
41
42
43
44
45
46
47
48
49

50 **Outcomes**

51 Primarily, we sought to determine the proportion of patients discharged from hospital with
52 acute VTE that were prescribed a traditional therapy (parenteral anticoagulant ± warfarin) or a DOAC.
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Secondarily, we sought to compare differences in management between those in the Edmonton area, Regina area and rural Alberta. Use of DOACs for PE versus DVT was compared, as well as whether clot burden influenced anticoagulant selection. DVT was classified as proximal (at or above the popliteal vein including the trifurcation area) or distal in the leg. For PE, the validated simplified Pulmonary Embolism Severity Indices (sPESI) of either 0 or ≥ 1 was used, calculated at the time of presentation of the PE.^{14,15}

When prescribed, the use of DOACs was assessed for concordance with dosing regimens with Health Canada approved product monographs as per prescriptions received both in hospital and as planned at the point of discharge.¹⁻⁴ DOAC dosing was considered concordant if therapy was provided with either a parenteral anticoagulant or the appropriate up front (larger dose) of rivaroxaban (15mg BID) or apixaban (10mg BID) for the appropriate duration (3 and 1 week, respectively). We also assessed the difference in length of hospital stay in patients prescribed a DOAC versus a traditional therapy, and with whom follow-up was to occur after discharge.

Notably, these data represent a detailed evaluation specific to patients hospitalized with acute VTE. Our audit also encompassed the cohort of patients discharged directly from emergency departments from all institutions. As per our pre-planned analysis, there are 2 other manuscripts under review; one detailing the emergency department cohort and the other comparing (in aggregate amongst the urban settings) patents discharged directly from the emergency department versus those hospitalized.^{16,17}

Patient and Public Involvement Statement

Patients and or the public were not involved in this study.

Analysis

Data analysis was performed at the Epidemiology Coordinating and Research (EPICORE) Centre. All data is contained within REDCap, University of Alberta, and are available to the principal investigator (TJB). No data sharing agreement is in place. Data were collated and reported based on location, namely

1
2
3 Edmonton area, Regina area and rural Alberta. Patients' characteristics were compared between sites
4 using mean (SD) or median (IQR) as appropriate for the continuous data and proportions (%) for
5
6 categorical data. Chi-square test was used to compare discharge therapies between sites and different
7
8 groups. Statistical analysis was carried out on SAS version 9.4. Health Research Ethics Board approval
9
10 was received through the University of Alberta (Pro00056384) for all Alberta sites, and via the Regina
11
12 Qu'Appelle Health Region (REB 15-65) for the Regina sites.
13
14

15 RESULTS

16
17 A total of 958 charts were screened with 695 (72.5%) included (Figure 1). The most common
18
19 reasons for exclusion were lack of an acute VTE diagnosis (39.9%) and another indication for therapeutic
20
21 anticoagulation (23.6%). Overall, those included had an average age (\pm SD) of 63.3 ± 17.3 years, a median
22
23 body weight of 85.5Kg and only a minority (3.5%) had a creatinine clearance (CrCl) <30 mL/min (Table 1).
24
25 The majority of patients had PE (82.9%), particularly in the urban centres of Edmonton (84.4%) and
26
27 Regina (80.8%), while the diagnosis of PE was lower in rural Alberta (63.3%). Based on the sPESI score,
28
29 the majority with PE in Edmonton (66.5%) and Regina (58.8%) had a PESI score ≥ 1 , while rural Alberta
30
31 was nearly half the patients (47.4%). The majority of patients admitted for DVT had a proximal clot;
32
33 Edmonton (87.1%), rural Alberta (81.8%), Regina (69.6%). Of note, full leg ultrasounds were utilized in
34
35 Regina while only above the knee ultrasounds were utilized in both Edmonton and rural Alberta.
36
37
38
39

40
41 The majority of patients (70.2%) were discharged from hospital on a traditional therapy
42
43 (parenteral anticoagulant +/- warfarin), with 28.3% receiving a DOAC (Table 2). Notably, Regina had the
44
45 highest rate of a warfarin-based regimen (60.8%), with less warfarin used in Edmonton (40.5%) and rural
46
47 Alberta (30%) ($P<0.0001$). Use of DOACs was most common in rural Alberta (57.9%), followed by
48
49 Edmonton (28.3%) and Regina (23.3%) ($P<0.0001$).
50
51

52
53 There was no difference in proportionate use of a DOAC for PE compared to DVT (28.0% and
54
55 30.3%, respectively; $P=0.61$). Patients having a sPESI score of 0 were more likely to be prescribed a
56
57
58
59

DOAC relative to those with a score ≥ 1 (33.3% and 24.3%, respectively; $P < 0.0001$). Only a small portion of patients in our study had distal DVTs (N=13) compared with proximal DVTs (N=99), leaving too few to perform statistical comparisons.

Amongst the 197 patients prescribed a DOAC, the majority (97.5%) received rivaroxaban, with a minority of patients receiving apixaban (N=3 [1.5%]) and dabigatran (N=2 [1.0%]). DOAC dosing for the acute treatment of VTE was consistent with product monographs in 85.8% of patients. The majority of inconsistent dosing with rivaroxaban was attributable to not having a full 3 weeks of therapy of higher dose (rivaroxaban 15mg BID) prior to implementing the lower maintenance dose of 20mg daily (N=25/28). Amongst these 25 patients, 5 had < 7 days of rivaroxaban 15mg BID and 10 patients completed both 7-14 and 14-20 days of this regimen. Only a minority of patients had renal dysfunction with a CrCl < 30 mL/min (N=23 [3.5%]). DOAC use declined with worsening renal function with 31.1% (161/517), 19.0% (23/121), and 4.4% (1/23) prescribed a DOAC with a CrCl > 50 , 30-50 and < 30 mL/min, respectively ($P < 0.0001$).

Combining all sites, median (IQR) length of stay was shortest amongst those prescribed a DOAC (4 days [2.0, 9.0]) and longest for those transitioning from LMWH to warfarin therapy (7 days [4.0, 12.0]) ($P < 0.0001$) (Table 3). At discharge, amongst the urban sites follow-up was to occur most commonly with a VTE clinic/specialist (47.5% for Edmonton and 52.5% with Regina) whereas rural Alberta referred most to family doctors (66.7%) (Table 2).

DISCUSSION

Amongst all sites, the majority (70.2%) of patients presenting with acute VTE were prescribed traditional therapies (parenteral anticoagulant +/- warfarin) at hospital discharge, and 28.3% received a DOAC. Rural Alberta had the greatest uptake of the DOACs (50%), followed by the Edmonton area (28.3%) and Regina area (23.3%). Uptake of DOACs in rural Alberta is likely attributable to many factors, including more limited laboratory availability for routine coagulation testing, primary care physicians

1
2
3 providing care within the hospital and hospital pharmacists who were comfortable with data pertaining
4 to the use of DOACs in this population. While we found no difference in the use of DOACs for PE relative
5 to DVT, DOACs were used more in patients with lower risk PE and normal renal function. When
6 prescribed, the majority of DOAC use (85.8%) was concordant with Canadian product labeling.
7
8
9

10
11 Our overall rate of DOAC use for acute VTE (28.3%) is similar to that reported amongst 328
12 patients discharged from Florence, Italy hospitals following acute PE (32.5%) during 2014 and 2015.¹⁸
13 These investigators assessed a time interval that partially overlapped with ours, and report an increase
14 in DOAC use from 2014 (23.2%) to 2015 (40.1%). A single site evaluation of therapy for an incident VTE
15 presentation amongst 256 patients in Montreal, Quebec Canada in 2013 found similar overall trends to
16 our study with most patients being treated with warfarin (54.7%) followed by LMWH alone (27.7%) and
17 rivaroxaban (17.6%).¹⁹ Unlike our study, those in the Quebec evaluation with DVT (N=94) were more
18 likely than those with PE (N=162) to receive rivaroxaban (28.7% and 11.1%, respectively). In terms of
19 clinical presentation of PE, a single site evaluation of 39 patients with PE being discharged from hospital
20 on a DOAC showed more use amongst those defined as low risk (83%), with overall DOAC use still being
21 high for those at intermediate-low risk (40%), intermediate-high risk (68%) and high risk (40%).¹⁸ Our
22 study found similar results in that more patients with a sPESI score of 0 (33.3%) received DOACs,
23 however DOACs were still used amongst those with a score of ≥ 1 (24.3%).
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 Concordance with dosing for acute VTE in our study (85.8%) was similar to that reported in an
42 audit assessing the appropriateness of DOAC prescribing amongst 39 VTE patients in Australia (84.6%)²⁰
43 and lower than that reported in a non-interventional study assessing the use of the appropriate initial
44 dosing of rivaroxaban (93.7%).²¹ Unlike our study wherein the majority of patients not receiving DOAC
45 dosing per the product monographs due to not receiving the appropriate up front rivaroxaban 15mg
46 BID, the non-interventional study reported that only 73% of patients went onto step down to
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 rivaroxaban 20mg daily.²¹ Unfortunately, we were not able to identify therapy changes beyond that
4
5 planned at hospital discharge within our study.
6
7

8 Given that initial therapy with an injectable anticoagulant is not required for both rivaroxaban
9
10 and apixaban and that routine coagulation monitoring is not performed with all of the DOACs, care
11
12 delivery with a DOACs compared to traditional therapy with a parenteral anticoagulant ± warfarin
13
14 should be simplified. Data from the North American cohort of patients enrolled in landmark trials
15
16 reports a significantly shorter length of stay for those receiving rivaroxaban (3.0 days [3.0-5.0])
17
18 compared to traditional therapy (4.0 days [3.0-6.0]; P=0.0004).²² A single site evaluation in Quebec,
19
20 Canada affirmed the clinical trial data, and reported median length of stay to be shorter with
21
22 rivaroxaban use (3.5 days) relative to LMWH alone or warfarin therapy (6 days).¹⁹ Similarly, a single
23
24 American institution identified those discharged on rivaroxaban compared to warfarin had shorter
25
26 hospital stays (3.5 and 7 days, respectively; P<0.001).²³ Our study also identified a shorter length of stay
27
28 amongst patients receiving a DOAC, consistent with these data (Table 3).^{19,22,23} Our results, however,
29
30 may have been confounded by those having more severe thrombosis receiving traditional therapies.
31
32
33

34 **STRENGTHS AND LIMITATIONS**

35
36 Herein we present a large cohort of patients with acute VTE being discharged following
37
38 hospitalization. For all sites, we reviewed all medical records with a discharge diagnosis of deep vein
39
40 thrombosis (DVT) (ICD-10 code I82 + sub-indices) or pulmonary embolism (PE) (ICD-10 code I26 + sub-
41
42 indices) over the span of a full year (April 2014 to March 2015). In doing so, different sample sizes were
43
44 identified from each area, with rural Alberta and Regina having fewer patients (N=30 and N=120,
45
46 respectively) than the Edmonton area (N=545). Despite the differences in sample sizes, these data
47
48 reflect local practices given the geographic populations and catchment areas (Edmonton: 1,328,290 plus
49
50 catchment of ~500,000; Regina: 230,020 plus catchment of 500,000; rural Alberta 3 sites: 30,065) and
51
52 that an entire year was assessed.²⁴⁻²⁸ The timing of our audit is reflective of the early uptake of DOACs
53
54
55
56
57
58
59
60

1
2
3 for the acute treatment of VTE given only rivaroxaban had Health Canada approval throughout the
4
5 entire time interval audited. Provincial remuneration was only starting to occur, only being in place for
6
7 rivaroxaban for the duration of the audit year for DVT in both provinces and for PE in June 2014 for
8
9 Saskatchewan (beyond the audit year for PE in Alberta). Given the timing of approval and remuneration,
10
11 prescribing patterns may have changed beyond the timing of this audit (March 2015). Despite this, we
12
13 identified reasonable uptake of the DOACs (28.3%), with use that complied with product monograph
14
15 labeling in the vast majority (85.8%). This data can serve as a marker for future analyses wherein usage
16
17 can be compared to assess the uptake of this therapeutic approach over time as guidelines more
18
19 aggressively incorporate the utilization of DOACs in this population and clinicians become more
20
21 comfortable with their use.
22
23

24
25 Our design (retrospective medical record review) was selected to allow us to accurately select
26
27 patients with acute VTE to ascertain practice patterns. Given the diverse geography and volume of
28
29 records to review, 3 data abstractors were necessary. A master key defining eligibility, data points to
30
31 collect and how to code variables in REDCap was used. Within REDCap, restrictions for variables were
32
33 programmed to minimize data entry error. Prior to finishing data collection at each site, quality
34
35 assurance reports were performed to ensure accuracy of data. As this was a record review, we were
36
37 limited only to information available in the hospital-based chart. Given this, some data elements were
38
39 not documented (e.g., weight, serum creatinine), leaving us to report data for those available.
40
41 Moreover, our design did not enable us to collect data following hospital discharge, limiting us from
42
43 determining if patients got their prescriptions filled or had complications following discharge.
44
45
46

47 **CONCLUSION**

48
49 In summary, we report the management of a large cohort of acute VTE patients being
50
51 discharged from hospitals within Canada. Over a time interval early in the approval process for DOACs
52
53 for the acute treatment of VTE, we report a modest uptake of DOACs (28.3%) that were, overall, dosed
54
55
56
57
58
59

1
2
3 correctly for the majority of patients (85.8%). Variation in therapies used was evident with the most
4 common regimen being warfarin-based in Regina (60.7%) and Edmonton (40.5%) and a DOAC in rural
5 Alberta (50.5%) ($P < 0.0001$). Use of rivaroxaban was proportionately higher for less severe clots, and
6 those prescribed a DOAC had a shorter length of stay relative to those given traditional therapies. As
7 time evolves, it is anticipated use of DOACs will increase for the management of VTE. Practitioners and
8 health delivery systems should continue to consider the opportunity provided by the DOACs to simplify
9 and shorten hospital based care as further data emerges to support their place in therapy. Future
10 evaluations should occur to assess temporal changes, ongoing appropriateness of care delivery and the
11 impact that DOACs may have on healthcare system resource allocation.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Pfizer Canada Inc, Kirkland, Quebec and Bristol-Myers Squibb Canada, Montreal, Quebec. Eliquis™ Product Monograph. Montreal, Quebec.
http://www.pfizer.ca/sites/g/files/g10028126/f/201607/ELIQUIS_PM_184464_16June2016_E_mar_keted.pdf Accessed 9 February 2017
2. Daiichi Sankyo, Inc, Parsippany, NJ, USA (Manufacturer); Progress Therapeutics, Newmarket, Ontario (Importer and Distributer). Lixiana™ Product Monograph.
https://pdf.hres.ca/dpd_pm/00037831.PDF Accessed 9 February 2017
3. Boehringer Ingelheim Canada Ltd. Pradaxa™ Product Monograph, Burlington, Ontario.
<https://www.boehringer-ingelheim.ca/sites/ca/files/documents/pradaxapmen.pdf> Accessed 9 February 2017
4. Bayer Inc. Xarelto™ Product Monograph. Toronto, Ontario. Available:
<http://omr.bayer.ca/omr/online/xarelto-pm-en.pdf> Accessed 9 February 2017
5. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M et al for the AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369:799-808. doi: 10.1056/NEJMoa1302507
6. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H et al for the RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361:2342-52. doi: 10.1056/NEJMoa0906598
7. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Erikson H, Mismetti P et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circ 2014;129:764-772. doi: 10.1161/CIRCULATIONAHA.113.004450
8. The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510. doi:10.1056/NEJMoa1007903

- 1
2
3 9. The EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary
4 embolism. *N Engl J Med* 2012;366:1287-97. doi:10.1056/NEJMoa1113572
5
6
- 7
8 10. The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous
9 thromboembolism. *N Engl J Med* 2013;369:1406-1415. doi: 10.1056/NEJMoa1306638
10
11
- 12 11. Finks SW, Trujillo TC, Dobesh PP (2016) Management of venous thromboembolism: recent
13 advances in oral anticoagulation therapy. *Ann Pharmacother* 50:486-501. doi:
14 10.1177/1060028016632785
15
16
- 17
18 12. Kearon C, Akl EA, Comerota AJ, Prandoni P et al. Antithrombotic therapy for VTE disease:
19 Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest
20 Physicians Evidence-based clinical practice guidelines. *CHEST* 2012;141:e419S-494S.
21
22
- 23 13. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H et al. Antithrombotic
24 therapy for VTE disease: CHEST guideline and expert panel report. *CHEST* 2016;149(2):315-
25 352.
26
27
- 28 14. Chan CM, Woods C, Shorr AF. The validation and reproducibility of the pulmonary embolism
29 severity index. *J Thromb Haemost* 2010;8:1509-1514. Doi: 10.1111/j.1538-7836.2010.03888.x.
30
31
- 32 15. Righini M, Roy PM, Meyer G, Verschuren F, Aujesky D, Le Gal G. The simplified pulmonary
33 embolism severity index (PESI): validation of a clinical prognostic model for pulmonary embolism. *J*
34 *Thromb Haemost* 2011;9:2001-2007. doi: 10.1111/j.1538-7836.2011.04469.x.
35
36
- 37 16. Bungard TJ, Ritchie B, Bolt J, Semchuk W. Management of acute venous thromboembolism amongst
38 a cohort of patients discharged directly from the emergency department. *BMJ Open*, Under
39 Review, February 2018.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 17. Bungard TJ, Ritchie B, Bolt J, Semchuk W. Anticoagulant therapies for acute venous
4 thromboembolism: A comparison between those discharged directly from the emergency
5 department versus hospitalized in 2 Canadian cities. *BMJ Open*, Under Review, February 2018.
6
7
8
9
10 18. Masotti L, Vannucchi V, Poggi M, Landini G. Trends in length of hospital stay in acute pulmonary
11 embolism over the years. What is changing in the era of direct oral anticoagulants? *J Cardiovasc*
12 *Med* 2015;17:817-823. doi: 10.2459/JCM.0000000000000356
13
14
15
16 19. Dault R, Vanasse A, Blais L, Perreault S, Farand P, Le Templier G et al. Patterns of predictors of use
17 of anticoagulants for the treatment of venous thromboembolism following approval of rivaroxaban.
18 *Clin Appl Thromb Hemost* 2016;22:765-771. doi: 10.1177/1076029615611249
19
20
21
22
23 20. Pattullo CS, Barras M, Tai B, McKean M, Donovan P. New oral anticoagulants: appropriateness of
24 prescribing in a real-world setting. *Int Med J* 2016;46:812-818. doi: 10.1111/imj.13118
25
26
27
28 21. Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J et al. Safety and effectiveness of
29 oral rivaroxaban versus standard anticoagulation for the symptomatic deep-vein thrombosis
30 (XALIA): an international, prospective, non-interventional study. *Lancet Haematol* 2016;3:e12-21.
31 doi: hggp://dx.doi.org/10.1016/S2353-3026(15)00257-4
32
33
34
35
36 22. Bookhart BK, Haskell L, Bamber L, Wang M, Schein J, Mody SH. Length of stay and economic
37 consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE:
38 findings from the North American EINSTEIN clinical trial program. *J Med Econ* 2014;17:1691-695.
39 doi: 10.3111/13696998.2014.946993
40
41
42
43
44
45 23. Desai A, Desai A, Calixte R, Aparnath M, Hindenburg A, Salzman S et al. Comparing length of stay
46 between patients taking rivaroxaban and conventional anticoagulants for treatment of venous
47 thromboembolism. *Lung* 2016;194:605-611. doi:10.1007/s00408-016-9898-8
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 24. Population of Edmonton area, accessed October 31, 2017:
4

5 [http://globalnews.ca/news/1824910/edmonton-region-has-canadas-2nd-highest-population-](http://globalnews.ca/news/1824910/edmonton-region-has-canadas-2nd-highest-population-growth-stats-canada/)
6 [growth-stats-canada/](http://globalnews.ca/news/1824910/edmonton-region-has-canadas-2nd-highest-population-growth-stats-canada/)
7
8
9

10 25. Population of Regina, accessed October 31, 2017:

11 <http://www.leaderpost.com/life/Regina+population+cracks/9553267/story.html>
12
13

14 26. Athabasca Population, accessed October 31, 2017: [http://www.city-data.com/canada/Athabasca-](http://www.city-data.com/canada/Athabasca-Town.html)
15 [Town.html](http://www.city-data.com/canada/Athabasca-Town.html)
16
17

18 27. Westlock Population, accessed October 31, 2017: [http://www.city-data.com/canada/Westlock-](http://www.city-data.com/canada/Westlock-Town.html)
19 [Town.html](http://www.city-data.com/canada/Westlock-Town.html)
20
21
22

23 28. Wetaskiwin Population, accessed October 31, 2017:

24 <https://www.wetaskiwin.ca/DocumentCenter/View/1039>
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DATA SHARING AGREEMENT

There is no data sharing agreement – this is included in the original research article.

AUTHOR CONTRIBUTIONS

TJB contributed to the design of the work, the acquisition, analysis and interpretation of the data. TJB drafted the original manuscript, approved the final version to be published and is accountable for all aspects of the work related to accuracy or integrity. BR contributed to the design of the work, the interpretation of the data and critically revised the manuscript. BR approved the final version to be published and is accountable for all aspects of the work related to accuracy or integrity. JB contributed to the acquisition and interpretation of the data, critically revised the manuscript and approved the final version to be published. JB is accountable for all aspects of the work related to accuracy or integrity. WS contributed to the design, acquisition and interpretation of the data, critically revised the manuscript and approved the final version to be published. WS is also accountable for the accuracy and integrity of this work.

Figure 1: Patient Flow

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Baseline Characteristics

	Total	Edmonton	Rural Alberta	Regina
Screened (N)	958	736	41	181
Included (N, %)	695 (72.5%)	545 (74.0%)	30 (73.2%)	120 (66.3%)
Male (N, %)	350 (50.4%)	282 (51.7%)	16 (53.3%)	52 (43.3%)
Mean age (mean \pm SD)	63.3 \pm 17.3	63.8 \pm 17.2	64.2 \pm 16.9	60.4 \pm 17.6
Weight Documented (N, %) ^a	680 (97.8%)	534 (98.0%)	28 (93.3%)	118 (98.3%)
Weight, Kg (Median, IQR)	85.5 (70.0, 106.0)	84.5 (70.0, 106.0)	84.3 (71.0, 98.3)	90.5 (70.0, 110.0)
CrCl Documented (N, %) ^a	661 (95.0%)	515 (94.5%)	29 (96.7%)	117 (97.5%)
< 30 mL/min	23 (3.5%)	20 (3.9%)	1 (3.5%)	2 (1.7%)
30-49 mL/min	121 (18.3%)	96 (18.6%)	3 (10.3%)	22 (18.8%)
> 50 mL/min	517 (78.2%)	399 (77.5%)	25 (86.2%)	93 (79.5%)
VTE				
DVT	119 (17.1%)	85 (15.6%)	11 (36.6%)	23 (19.2%)
Distal	13 (10.9%)	7 (8.2%)	0	6 (26.1%)
Proximal ^b	99 (83.2%)	74 (87.1%)	9 (81.8%)	16 (69.6%)
Not documented	7 (5.9%)	4 (4.7%)	2 (18.2%)	1 (4.3%)
PE and PE + DVT ^c	576 (82.9%)	460 (84.4%)	19 (63.3%)	97 (80.8%)
PE – Simplified PESI Score: ^d	567 (98.4%)	451 (98.0%)	19 (100%)	97 (100%)
0 point	201 (35.4%)	151 (33.5%)	10 (52.6%)	40 (41.2%)
\geq 1 points	366 (64.6%)	300 (66.5%)	9 (47.4%)	57 (58.8%)
History of:				
Cancer	158 (22.7%)	119 (21.8%)	10 (33.3%)	29 (24.2%)
Pulmonary disease	143 (20.6%)	114 (20.9%)	6 (20.0%)	23 (19.2%)
Prior VTE	100 (14.4%)	81 (14.9%)	6 (20.0%)	13 (10.8%)
Recent surgery	32 (4.6%)	23 (4.2%)	0	9 (7.5%)
Length of Stay (median, IQR)	6.0 (3.0, 11.0)	6.0 (3.0, 11.0)	5.5 (3.0, 13.0)	6.0 (3.0, 9.0)

CrCl=Creatinine Clearance; SD=Standard Deviation; IQR=Interquartile Range; PE=Pulmonary Embolism; DVT=Deep Vein Thrombosis; PESI=Pulmonary Embolism Severity Index; LOS=Length of Stay

^anot all patients had weight and serum creatinine documented in the chart

^bCombined popliteal, femoral, common femoral, and iliac

^ccombined PE with PE+DVT and report it all as PE

^dPESI score could not be calculated in 9 patients due to missing variable(s)

Table 2: Therapy at Discharge and Follow-Up Plan for Hospitalized Cohort

	Total	Edmonton	Rural Alberta	Regina	P Value
VTE (All Combined)					<0.0001*
Parenteral AC alone	185 (26.6%)	160 (29.4%)	6 (20.0%)	19 (15.8%)	
Parenteral AC + warfarin	145 (20.9%)	83 (15.2%)	4 (13.3%)	58 (48.3%)	
Warfarin	158 (22.7%)	138 (25.3%)	5 (16.7%)	15 (12.5%)	
DOAC	197 (28.3%)	154 (28.3%)	15 (50.0%)	28 (23.3%)	
Rivaroxaban	192 (97.5%)	151 (98.1%)	14 (93.3%)	27 (96.4%)	
Dabigatran	2 (1.0%)	0	1 (6.7%)	1 (3.6%)	
Apixaban	3 (1.5%)	3 (2.0%)	0	0	
Not Documented	10 (1.4%)	10 (1.8%)	0	0	
PE and PE+DVT					<0.0001*
Parenteral AC alone	146 (25.3%)	129 (28.0%)	5 (26.3%)	12 (12.4%)	
Parenteral AC + warfarin	129 (22.4%)	77 (16.7%)	1 (5.3%)	51 (52.6%)	
Warfarin	132 (22.9%)	119 (25.8%)	2 (10.5%)	11 (11.3%)	
DOAC	161 (28.0%)	127 (27.6%)	11 (57.9%)	23 (23.7%)	
Rivaroxaban	156 (96.9%)	124 (97.6%)	10 (90.9%)	22 (95.6%)	
Dabigatran	2 (1.2%)	0	1 (9.1%)	1 (4.4%)	
Apixaban	3 (1.9%)	3 (2.4)	0	0	
Not Documented	8 (1.4%)	8 (1.7%)	0	0	
DVT alone					0.045*
Parenteral AC alone	39 (32.8%)	31 (36.5%)	1 (9.1%)	7 (30.4%)	
Parenteral AC + warfarin	16 (13.4%)	6 (7.1%)	3 (2.7%)	7 (30.4%)	
Warfarin	26 (21.8%)	19 (22.4%)	3 (27.3%)	4 (17.4%)	
DOAC	36 (30.3%)	27 (31.8%)	4 (36.4%)	5 (21.7%)	
Rivaroxaban	36 (100%)	27 (100.0%)	4 (100.0%)	5 (100.0%)	
Dabigatran	0	0	0	0	
Apixaban	0	0	0	0	
Not Documented	2 (1.7%)	2 (2.4%)	0	0	
Follow-Up					
Family Doctor	358 (51.5%)	276 (50.6%)	20 (66.7%)	62 (51.7%)	P=0.23
VTE Clinic	202 (29.1%)	201 (36.9%)	1 (3.3%)	0	P<0.001
Specialist	124 (17.8%)	58 (10.6%)	3 (10.0%)	63 (52.5%)	P<0.001
Anticoagulation Clinic	34 (4.9%)	10 (1.8%)	0	24 (20.0%)	P<0.001

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Return to ED	10 (1.4%)	8 (1.5%)	2 (6.7%)	0	P=0.045
Other	101 (14.5%)	90 (16.5%)	6 (20.0%)	5 (4.2%)	
Not documented	41 (5.9%)	33 (6.1%)	2 (6.7%)	6 (5.0%)	

VTE=Venous Thromboembolism; PE=Pulmonary Embolism; DVT=Deep Vein Thrombosis; DOAC=Direct Oral Anticoagulant; AC=Anticoagulant; ED=Emergency Department

*P value compares therapies (categorized as parenteral anticoagulant alone, parenteral anticoagulant with warfarin, warfarin or a direct acting anticoagulant) used across the 3 settings

For peer review only

Table 3: Length of Stay in Days (Median, IQR) Based on Therapy


Therapy	All	Edmonton	Rural Alberta	Regina
DOAC	4 (2.0, 9.0)	4 (2.0, 8.0)	6 (2.0, 19.0)	4.5 (2.0, 8.5)
Parenteral Alone	5 (3.0, 10.0)	5 (2.0, 9.0)	15 (5.0, 21.0)	6 (4.0, 10.0)
Parenteral + Warfarin / Warfarin alone	7 (4.0, 12.0)	8 (4.0, 14.0)	4 (2.0, 6.0)	7 (4.0, 9.0)
P Value	<0.0001	<0.0001	0.091	0.223

DOAC=Direct Oral Anticoagulant

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Patient Flow



165x95mm (300 x 300 DPI)

Review only

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2-3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	6-7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	7
Study size	10	Explain how the study size was arrived at	NA-full year of data
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	7-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	7
		(d) If applicable, explain how loss to follow-up was addressed	NA
		(e) Describe any sensitivity analyses	NA
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	8, Figure 1
		(b) Give reasons for non-participation at each stage	8, Figure 1
		(c) Consider use of a flow diagram	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	8, Table 1
		(b) Indicate number of participants with missing data for each variable of interest	Table 1
		(c) Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	Report numbers of outcome events or summary measures over time	8-9
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	NA
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	9
Discussion			
Key results	18	Summarise key results with reference to study objectives	9-10
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	10-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	4

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.